

**ONTARIO
SUPERIOR COURT OF JUSTICE
(COMMERCIAL LIST)**

**IN THE MATTER OF THE *COMPANIES' CREDITORS ARRANGEMENT ACT*,
R.S.C. 1985, c. C-36, AS AMENDED**

**AND IN THE MATTER OF A PLAN OF COMPROMISE OR ARRANGEMENT
OF CANNTRUST HOLDINGS INC., CANNTRUST INC., CTI HOLDINGS
(OSOYOOS) INC., and ELMCLIFFE INVESTMENTS INC.
Applicants**

**MOTION RECORD OF
ZOLA FINANCE HOLDINGS LTD. AND IGOR GIMELSHTAIN
(Responding to Proposed CCAA Representation Order)**

January 28, 2021

Wright Henry LLP
200 Wellington Street West, Suite 602
Toronto ON M5V 3C7
Tel: 416-306-8280
Fax: 416-306-8281

Michael D. Wright, LSO# 32522T
mwright@wrighthenry.ca

Danielle Stampley, LSO# 69487C
dstampley@wrighthenry.ca

Lawyers for Zola Finance Holdings Ltd. and
Igor Gimelshtein

AND

SISKINDS LLP

680 Waterloo Street
P.O. Box 2520
London, ON N6A 3V8
Tel: 519-660-2121
Fax: 519-672-6065

Michael G. Robb, LSO# 45787G
michael.robbs@siskinds.com

100 Lombard Street, Suite 302
Toronto, ON M5C 1M3
Tel: 416-594-4394
Fax: 416-362-2610

Alex Dimson, LSO# 56129U
alex.dimson@siskinds.com

Lawyers for Zola Finance Holdings Ltd. and
Igor Gimelshtein

TO: **ERNST & YOUNG INC.**
Ernst & Young Tower
100 Adelaide Street West
P.O. Box. 1
Toronto, ON M5H 0B3
Tel: 416-864-1234

Alex Morrison
alex.f.morrison@ca.ey.com

David Saldanha
david.saldanha@ca.ey.com

Karen Fung
karen.l.fung@ca.ey.com

Monitor

AND T O: **McCarthy, Tétrault LLP**
Barristers and Solicitors
TD Bank Tower
66 Wellington Street West
Suite 5300
Toronto, ON M5K 1E6
Fax: 416-868-0673

James D. Gage, LSO# 34676I
Tel: 416-601-7539
jgage@mccarthy.ca

Paul R. Steep, LSO# 21869L
Tel: 416-601-7998
psteep@mccarthy.ca

Shane D'Souza, LSO# 58241G
Tel: 416-601-8196
sdsouza@mccarthy.ca

Trevor Courtis, LSO# 67715A
Tel: 416-601-7643
tcourtis@mccarthy.ca

Alexander Steele, LSO# 75719P
Tel: 416-601-8370
asteele@mccarthy.ca

Lawyers for the Applicants, CannTrust Inc., CTI Holdings (Osoyoos) Inc. and
Elmcliffe Investments Inc. and the Applicant and Debtor, CannTrust Holdings Inc.

AND TO: **FTI Consulting Canada Inc.**
TD Waterhouse Tower
79 Wellington Street W
Toronto Dominion Centre
Suite 2010, PO Box 104
Toronto, ON M5K 1G8

Paul Bishop
Tel: 416-649-8100
paul.bishop@fticonsulting.com

Steven W. Bissell
Tel: 416-649-8054
steven.bissell@fticonsulting.com

Ellen Dong
Tel: 416-649-8091
ellen.dong@fticonsulting.com

Chief Restructuring Officer of the Applicants

AND TO: **Aird & Berlis LLP**
181 Bay Street, Suite 1800
P.O. Box 754
Toronto, ON M5J 2T9

Steven Graff, LSO# 31871V
Tel: 416-865-7726
sgraff@airdberlis.com

Jonathan Yantzi
Tel: 416-865-4733
jyantzi@airdberlis.com

Lawyers for the Monitor

AND TO: **THORNTON GROUT FINNIGAN LLP**
100 Wellington Street West, Suite 3200
P.O. Box 329, Toronto-Dominion Centre
Toronto, ON M5K 1K7

Robert I. Thornton
Tel: 416-304-0560
rthornton@tgf.ca

Leanne M. Williams
Tel: 416-304-0060
lwilliams@tgf.ca

Lawyers for Greenhill & Co. Canada Ltd.

AND TO: **Attorney General of Canada**
Department of Justice Canada
Ontario Regional Office, Tax Law Section
120 Adelaide Street West, Suite 400
Toronto, ON MGH 1T1
Fax: 416-973-0810

Diane Winters, General Counsel
Tel: 647-256-7459
diane.winters@justice.gc.ca

Maria Vujnovic
Tel: 647-256-7455
Maria.Vujnovic@justice.gc.ca

Lawyers for the Minister of National Revenue

AND TO: **Ministry of Finance (Ontario)**
Legal Services Branch
777 Bay Street, 11th Floor
Toronto, ON M5G 2C8
Tel: 416-327-8463

Kevin O'Hara
kevin.ohara@ontario.ca

AND TO: **Attorney of British Columbia**
Legal Services Branch, Revenue & Taxation
400-1675 Douglas Street
Victoria, BC V8W 9J7
Tel: 250-356-8589

Aaron Welch
aaron.welch@gov.bc.ca

AND TO: **Goldman, Spring, Kichler & Sanders LLP**
40 Sheppard Avenue West
Toronto, ON M2N 6K9
Tel: 416-225-9400

Mitchell J. Sanders
msanders@goldmanspring.com

Lawyers for CannTrust Holdings Inc.

AND TO: **TORYS LLP**
79 Wellington Street West, Suite 3000
Toronto, ON M5K 1N2

David Bish
Tel: 416-865-7380
dbish@torys.com

John Fabello
Tel: 416-865-8228
jfabello@torys.com

Gillian Dingle
Tel: 416-865-8229
gdingle@torys.com

Craig Gilchrist
Tel: 416-865-7629
cgilchrist@torys.com

Lawyers for Merrill Lynch Canada Inc., Jefferies Securities Inc., Credit Suisse Securities (Canada) Inc., Canaccord Genuity Corp., Citigroup Global Markets Canada Inc., and RBC Dominion Securities Inc.

AND TO: **MILLER THOMSON LLP**
255 Queens Avenue, Suite 2010
Toronto, ON N6A 5R8

Tony Van Klink
Tel: 519-931-3509
tvanklink@millerthomson.com

Lawyers for Bank of Montreal

AND TO: **FOGLER RUBINOFF LLP**
77 King Street West, Suite 3000
Toronto, ON M5K 1G8

Vern W. DaRe
Tel: 416-941-8842
vdare@foglers.com

Lawyers for Balfour Energy Corp.

AND TO: **HENEIN HUTCHISON LLP**
235 King Street East, First Floor
Toronto, ON, M5A 1J9

Marie Henein
Tel: 416-368-5000
mhenein@hhllp.ca

Scott Hutchison
Tel: 416-368-5000
shutchison@hhllp.ca

Mark Strychar-Bodnar
Tel: 416-368-5000
mstrychar.bodnar@hhllp.ca

Lauren Mills Taylor
Tel: 416-368-5000
lmillstaylor@hhllp.ca

Lawyers for the Ad Hoc Committee of Shareholders

AND TO: **KALLOGHLIAN MYERS LLP**
250 University Avenue, Suite 200
Toronto, ON M5H 3E5

Serge Kalloghlian
Tel: 647-812-5615
serge@kalloghlianmyers.com

Alexander Freedman
Tel: 647-812-5615
aj@kalloghlianmyers.com

Lawyers for the Ad Hoc Committee of Shareholders

AND TO: **A DIMITRI LASCARIS LAW
PROFESSIONAL CORPORATION**
G101-360 Rue Saint-Jacques
Montreal, QC H2Y 1P5

A Dimitri Lascaris
Tel: 514-941-5991
alexander.lascaris@gmail.com

Lawyers for the Ad Hoc Committee of Shareholders

AND TO: **STROSBERG SASSO SUTTS LLP**
1561 Ouellette Avenue
Windsor, ON N8X 1K5

Jay Strosberg
Tel: 519-561-6285
jay@strosbergco.com

David R. Wingfield
Tel: 519-561-6285
dwingfield@strosbergco.com

Justin Smith
Tel: 519-561-6285
jsmith@strosbergco.com

Lawyers for the Ad Hoc Committee of Shareholders

AND TO: **MORGANTI & CO., P.C.**
21 St Clair Avenue East
Toronto, ON M4T 1L9

Eli Karp
Tel: 647-344-1900
ekarp@morgantico.com

Sajjad Nematollahi
Tel: 647-344-1900
snematollahi@morgantico.com

Hadi Davarinia
Tel: 647-344-1900
hdavarinia@morgantico.com

Lawyers for Renato A. Piscioneri

AND TO: **CRAWLEY MACKEWN BRUSH LLP**
179 John Street, Suite 800
Toronto, ON M5T 1X4

Alistair Crawley
Tel: 416-217-0806
acrawley@cmblaw.ca

Jonathan Preece
Tel: 416-217-0897
jpreece@cmblaw.ca

Lawyers for Peter Aceto

AND TO: **STOCKWOODS LLP**
77 King Street West, Suite 4130
Toronto, ON M5K 1H1

Paul Le Vay
Tel: 416-593-2493
paully@stockwoods.ca

Gerald Chan
Tel: 416-593-1617
geraldc@stockwoods.ca

Carlo DiCarlo
Tel: 416-593-2485
carlodc@stockwoods.ca

Lawyers for Eric Paul

AND TO: **GOWLING WLG (CANADA) LLP**
1 First Canadian Place
100 King Street West, Suite 1600
Toronto, ON M5X 1G5

Thomas Gertner
Tel: 416-369-4618
thomas.gertner@gowlingwlg.com

Lawyers for KIK Holdco Company Inc.

AND TO: **SULLIVAN MAHONEY LLP**
40 Queen Street, P.O. Box 1360
St. Catharines, ON L2R 5K8

Peter Mahoney
Tel: 905-688-8490
pmahoney@sullivanmahoney.com

Lawyers for Verhoef Electric Inc.

AND TO: **MERCHANT LAW GROUP LLP**
400-2710 17th Avenue S.E.
Calgary, AB T2A 0P6

Evatt Merchant
Tel: 403-225-7777
emerchant@merchantlaw.com

Chris Simoes
Tel: 403-225-7777
csimoes@merchantlaw.com

Lawyers for 1604070 Alberta Ltd. representative plaintiff in respect of 1604070
Albert Ltd. v. CannTrust Holdings Inc., et al.

AND TO: **MERCHANT LAW GROUP LLP**
200-10 Notre-Dame Street East
Montreal, QC H2Y 1B7

Erik Lowe
Tel: 514-248-7777
elowe@merchantlaw.com

Lawyers for Diran Avedian, representative plaintiff in respect of Diran Avedian v.
CannTrust Holdings Inc., et al.

AND TO: **MERCHANT LAW GROUP LLP**
304-15127 100th Avenue
Surrey, BC V3R 0N9

Evatt Merchant
Tel: 604-951-0777
emerchant@merchantlaw.com

Steven Roxborough
Tel: 604-951-0777
sroxborough@merchantlaw.com

Lawyers for Jeff Dyck, representative plaintiff in respect of Jeff Dyck v. CannTrust
Holdings Inc., et al.

AND TO: **BLAKES, CASSELS & GRAYDON LLP**
199 Bay Street, Suite 4000
Toronto, ON M5L 1A9

Linc Rogers
Tel: 416-863-4168
linc.rogers@blakes.com

Caitlin McIntyre
Tel: 416-863-4174
caitlin.mcintyre@blakes.com

Lawyers for KPMG LLP

AND TO: **STIKEMAN ELLIOT LLP**
5300 Commerce Court West
199 Bay Street
Toronto, ON M5L 1B9

Peter Howard
Tel: 416-869-5613
phoward@stikeman.com

Ashley Taylor
Tel: 416-869-5623
ataylor@stikeman.com

Brian Pukier
Tel: 416-869-5567
bpukier@stikeman.com

Lawyers for Forum Financial Corp

AND TO: **ROCHON GENOVA**
121 Richmond Street West, Suite 900
Toronto, ON M5H 2K1

Joel P. Rochon
Tel: 416-363-1867
jrochon@rochongenova.com

Peter R. Jervis
Tel: 416-363-1867
pjervis@rochongenova.com

Douglas Worndl
Tel: 416-363-1867
dworndl@rochongenova.com

Ronald Podolny
Tel: 416-363-1867
rpodolny@rochongenova.com

Lawyers for Stephen Rosen

AND TO: **WEISZ FELL KOUR LLP**
100 King Street West
Suite 5600
Toronto, ON M5X 1C9

Steven Weisz
Tel: 416-613-8281
sweisz@wfklaw.ca

Canadian Lawyers for US Securities Class Action Claimants

AND TO: **LABATON SUCHAROW LLP**
140 Broadway
New York, New York 10015

James Johnson
Tel: 202-907-0859
jjohnson@labaton.com

Michael H. Rogers
Tel: 212-907-0814
mrogers@labaton.com

American Lawyers for US Securities Class Action Claimants

AND TO: **CHAITONS LLP**
5000 Yonge Street, 10th Floor
Toronto, ON M2N 7E9

Harvey Chaiton
Tel: 416-218-1129
harvey@chaitons.com

Lawyers for Single Dose Solutions Inc

AND TO: **THORNTON, GROUT & FINNIGAN LLP**
100 Wellington Street West, Suite 3200
Toronto, ON M5K 1K7

Mitch Grossell
Tel: 416-315-2864
mgrossell@tgf.ca

Lawyers for Andrew Peppin

AND TO: **KIRKLAND ELLIS LLP**
300 North LaSalle
Chicago, IL 60654

John Hartmann
Tel: 312-862-2215
jhartmann@kirkland.com

Jonathan Lahn
Tel: 312-862-2151
jlahn@kirkland.com

American Lawyers for KPMG

AND TO: **TRISURA GUARANTEE INSURANCE COMPANY**
333 Bay Street, Suite 1610, Box 22
Toronto, ON M5H 2R2

AND TO: **ENTERPRISE FLEET MANAGEMENT CANADA, INC.**
77 Belfield Road, Suite 100
Toronto, ON M9W 1G6

AND TO: **ENTERPRISE FLEET MANAGEMENT CANADA, INC.**
5821 6 Street SE
Calgary, AB T2H 1M4

AND TO: **RIGO LIFT TRUCK LIMITED**
175 Courtland Avenue
Concord, ON L4K 4T2

AND TO: **IMPACK PACKAGING SYSTEMS INC.**
445 Milner Avenue, Unit 4
Scarborough, ON M1B 2K4

AND TO: **BRITCO BOXX LIMITED PARTNERSHIP**
21690 Smith Crescent
Langley, BC V2Y 0W6

INDEX

	<u>TAB</u>	<u>PAGE</u>
Affidavit of Igor Gimelshtein sworn October 26, 2020	1	1
• Exhibit “A” – Statement of Claim issued on November 27, 2019	A	8
• Exhibit “B” – Cannabis Share Prices (July 2019 to October 2020)	B	74
Transcript of the Cross-Examination of Serge Kalloghlian on January 27, 2020	2	76

Court File No. CV-20-00638930-00CL

**ONTARIO
SUPERIOR COURT OF JUSTICE
(COMMERCIAL LIST)**

**IN THE MATTER OF THE *COMPANIES' CREDITORS ARRANGEMENT
ACT*, R.S.C. 1985, c. C-36, AS AMENDED**

**AND IN THE MATTER OF A PLAN OF COMPROMISE OR ARRANGEMENT OF
CANNTRUST HOLDINGS INC., CANNTRUST INC., CTI HOLDINGS (OSOYOOS)
INC., and ELMCLIFFE INVESTMENTS INC.**

Applicants

**AFFIDAVIT OF IGOR GIMELSHTAIN
(Sworn October 26, 2020)**

I, IGOR GIMELSHTAIN, of the City of Toronto, in the Province of Ontario AFFIRM:

1. Zola Finance Holdings Ltd. ("**Zola**") and I are plaintiffs in an action commenced in the Ontario Superior Court of Justice against CannTrust Holdings Ltd. ("**CannTrust**") and others, bearing the court file number CV-19-00002329-00CP (the "**Zola Action**"). The Zola Action was stayed when CannTrust obtained the initial order staying all proceedings under the *Canada Companies Creditor Arrangement Act* ("**CCAA**") on March 30, 2020.
2. I have knowledge of the matters deposed to below. Where I make statements in this affidavit that are not within my personal knowledge, I have indicated the source of my information and believe such information to be true.
3. I swear this affidavit in support of Zola and my opposition to CannTrust's motion to extend the CannTrust stay period until January 30, 2021.

MY BACKGROUND

4. I am a 2009 graduate of Western University's Richard Ivey School of Business, where I obtained an HBA. Upon graduation, I worked for over seven years in finance-related positions, including as an Investment Banking Analyst at Union Square Advisors LLC from 2008-2011 and as a Vice President at Birch Hill Equity Partners from 2011-2015.
5. In March 2015, I became Chief Financial Officer ("CFO") of MedReleaf Corp. ("**MedReleaf**"), then a privately owned cannabis company. I was directly involved in MedReleaf's successful Initial Public Offering, which resulted in MedReleaf shares trading on the TSE. MedReleaf was acquired by Aurora Cannabis for approximately \$3.2 billion CAD in June, 2018. I left MedReleaf in December, 2018.
6. MedReleaf was a licensed medical and recreational cannabis producer headquartered in Markham, Ontario. My responsibilities at MedReleaf included the following:
 - (a) Various financial responsibilities, including budgeting, reporting, forecasting and strategic business optimization;
 - (b) Various human resources responsibilities, including, hiring, terminations, promotions, incentive plan development and employee review process development;
 - (c) Assisting the Vice President of Quality Assurance in preparing for and responding to Health Canada audits and inspections performed by other government agencies and representatives; and
 - (d) Managing all floor level operations, which included:

- (i) The design and development of infrastructure to house cultivation and post-harvest operations;
 - (ii) The development of processes and timelines and optimization of schedules; and
 - (iii) Sales forecasting.
- 7. In mid-2018 my friend and colleague Tarik Ouass, who was a significant shareholder of MedReleaf, founded Zola. Zola is an operationally focused investment fund that is involved in investing in the legal cannabis industry, as well as other industries. Zola and I are often co-investors and we currently have investments in approximately 10 cannabis companies.
- 8. I have also served on the board of Columbia Care, a large cannabis producer, and regularly speak at international conferences on topics in the emerging cannabis sector.
- 9. As a result of my prior experiences I believe I have a strong understanding of cannabis companies' finances and operations.

ZOLA'S INVESTMENT IN CANNTRUST

- 10. In late September, 2018, Zola and I purchased 3 million shares of CannTrust, paying approximately \$37.8 million for the shares. In late October and early November, 2018 we sold 391,800 CannTrust shares. We continue to hold the remaining 2,608,2000 CannTrust shares.
- 11. On November 27, 2019, Zola and I commenced the Zola Action, which makes claims against CannTrust, Eric Paul and Fred Litwin, among others, for misleading us about the state of CannTrust's operations and its regulatory compliance. A copy of the Statement of Claim in the Zola Action is attached as **Exhibit "A."**

12. I believe that Zola is the single largest CannTrust shareholder to have retained counsel and participated in the CCAA process. It is also my belief that the only shareholders participating in the mediation process that has been ordered by this Court have or had much smaller ownership positions in CannTrust.

ZOLA'S CONCERNS ABOUT CANNTRUST'S CURRENT OPERATIONS

13. Since CannTrust filed for protection under the CCAA, Zola and I have carefully monitored CannTrust's financial state. Among other things, we have scrutinized all financial information that has been provided by the company prior to and during the CCAA process, including the monitors' reports and CannTrust's latest public financial statement, which reports on CannTrust's performance up to the first quarter of 2019.
14. We have also received and analyzed information that is covered by a confidentiality and non-disclosure agreement, which we cannot and do not reference in this section.
15. We have come to the conclusion that CannTrust's spending is unusually high and unjustified given its current operations. We have concluded that it is using its significant cash on hand, which it raised from investors like Zola and me pursuant to what we allege are wrongful acts, not only to maintain its operations but to expand them, although even that decision is not a sufficient explanation for the amount of cash being consumed.
16. We have repeatedly raised these concerns and our analysis with CannTrust and the Monitor, in a significant amount of detail, and received inadequate and untimely responses. This lack of responsiveness to the use or misuse of funds raised by our investment of over \$30 million CAD gives us concern about the good faith of CannTrust in this process. These funds would otherwise be available to resolve our outstanding claims.

17. Zola is very concerned about CannTrust's future prospects. It will be extremely difficult to be profitable in this economic climate. The cannabis industry is struggling and faces significant problems with declining prices and an oversupply of inventory. The top Canadian licensed producers of cannabis by market share have seen an average share price decline of greater than 72%. Attached as **Exhibit "B"** is a spreadsheet showing the share price of CannTrust's leading competitors at various points between July 5, 2019 to October 23, 2020.
18. Furthermore, it appears, based on my review of the Greg Guyatt's October 21, 2020 affidavit that CannTrust has not had any retail sales and states no intention to enter the retail market. CannTrust's sales to date have been exclusively in the bulk market, which I understand to be sales to other licensed producers. Based on my experience, the margin on bulk sales is substantially worse than on retail sales. In the current market, it would be near-impossible to operate profitably relying on bulk sales.

ZOLA'S INVOLVEMENT IN THE MEDIATION

19. Despite our desire to be an active participant in the ongoing mediation, which we have communicated to the mediator on several occasions, and even though we are significant CannTrust shareholders, Zola and I have been mostly excluded from the mediation process. In total our involvement in the mediation has consisted of:
- (a) Receiving summary memos from the mediator regarding the state of the mediation;
 - (b) Attending a CannTrust-led presentation, along with all other Plaintiffs counsel. We recently also had a meeting with a CannTrust executive accompanied by counsel for the Monitor and the company; and

- (c) Attending a single mediation session between us and CannTrust. In that session, which occurred in mid-August 2020, CannTrust made clear that they do not intend to negotiate directly with us and we have had no further settlement discussions.
20. I am advised by Alex Dimson, a lawyer at Siskinds LLP, that our counsel received an invite to attend a previously scheduled mediation session with a Defendant late the day before the session was to occur. However, counsel, was unable to attend the session on such short notice.
21. The coalition of lawyers representing various class action plaintiffs in the US and Canada that are actively negotiating with CannTrust has also refused to allow Zola, myself or our counsel to directly participate in settlement discussions. Zola has participated in two briefing sessions with the coalition where they provided us with a summary on the status of negotiations but they have made clear that they do not intend to allow us to participate directly in the process.
22. Furthermore, while the mediator's summary memos initially provided some detail about what offers were made in the mediation session, the latest memorandum from the mediator states that the mediator is not free to disclose the details of offers being exchanged. Neither Zola, myself or our counsel have been invited to or been advised of any future mediation sessions where we will be able to participate.

23. Accordingly we have effectively been excluded from the mediation process at this time, even though the main reason the stay is in place is to attempt to mediate a resolution of claims like ours.

SWORN before me over video)
teleconference in accordance with)
Ontario Regulation 431.20, with both)
the affiant and the commissioner)
being located in the City of Toronto,)
in the Province of Ontario, this 26th)
day of October, 2020.)

DocuSigned by:

Alex Dimson

6DBE7D0F8A024D6...

A Commissioner, etc.)

DocuSigned by:

Igor Gimelshtein

28BEF455B93B482...

Igor Gimelshtein

This is Exhibit "A" mentioned and referred to in the Affidavit of Igor Gimelshtein, sworn before me over video teleconference this 26th day of October, 2020, with both the affiant and the commissioner, Alex Dimson, being located in the City of Toronto, in the Province of Ontario.

DocuSigned by:

Alex Dimson

6DBE7D0F8A024D6...

A Commissioner, etc.



Court File No.:

**ONTARIO
SUPERIOR COURT OF JUSTICE**

Electronically issued
Délivré par voie électronique : 27-Nov-2019
London

ZOLA FINANCE HOLDINGS LTD. and IGOR GIMELSHTAIN

Plaintiffs

- and -

**CANNTRUST HOLDINGS INC., ERIC PAUL, PETER ACETO, FRED LITWIN, MARK
LITWIN, MITCHELL SANDERS, MARK DAWBER, ROBERT MARCOVITCH, SHAWNA
PAGE, JOHN KADEN, IAN ABRAMOWITZ, and BRAD ROGERS**

Defendants

Proceeding under the *Class Proceedings Act, 1992*

STATEMENT OF CLAIM

TO THE DEFENDANTS:

A LEGAL PROCEEDING HAS BEEN COMMENCED AGAINST YOU by the plaintiff. The claim made against you is set out in the following pages.

IF YOU WISH TO DEFEND THIS PROCEEDING, you or an Ontario lawyer acting for you must prepare a statement of defence in Form 18A prescribed by the *Rules of Civil Procedure*, serve it on the plaintiffs' lawyers or, where the plaintiffs do not have a lawyer, serve it on the plaintiff, and file it, with proof of service, in this court office, WITHIN TWENTY DAYS after this statement of claim is served on you, if you are served in Ontario.

If you are served in another province or territory of Canada or in the United States of America, the period for serving and filing your statement of defence is forty days. If you are served outside Canada and the United States of America, the period is sixty days.

Instead of serving and filing a statement of defence, you may serve and file a notice of intent to defend in Form 18B prescribed by the *Rules of Civil Procedure*. This will entitle you to ten more days within which to serve and file your statement of defence.

IF YOU FAIL TO DEFEND THIS PROCEEDING, JUDGMENT MAY BE GIVEN AGAINST YOU IN YOUR ABSENCE AND WITHOUT FURTHER NOTICE TO YOU. IF YOU WISH TO DEFEND THIS PROCEEDING BUT ARE UNABLE TO PAY LEGAL FEES, LEGAL AID MAY BE AVAILABLE TO YOU BY CONTACTING A LOCAL LEGAL AID OFFICE.

IF YOU PAY THE PLAINTIFFS' CLAIM, and \$1,000.00 for costs, within the time for serving and filing your statement of defence, you may move to have this proceeding dismissed

by the court. If you believe the amount claimed for costs is excessive, you may pay the plaintiffs' claim and \$400.00 for costs and have the costs assessed by the court.

TAKE NOTICE: THIS ACTION WILL AUTOMATICALLY BE DISMISSED if it has not been set down for trial or terminated by any means within five years after the action was commenced unless otherwise ordered by the court.

Date: November 27, 2019

Issued by: _____

Local Registrar

Address of Court Office:
Superior Court of Justice
80 Dundas St,
London, ON N6A 6K1

TO: CannTrust Holdings Inc.
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Eric Paul
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Peter Aceto
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Mark Litwin
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Mitchell Sanders
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Mark Dawber
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Robert Marcovitch
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Shawn Page
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: John Kaden
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Ian Abramowitz
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Brad Rogers
c/o 7300 Keele Street
Vaughan, ON L4K 1Z9

AND TO: Fred Litwin
c/o Forum Financial Corporation
106 Avenue Road
Toronto, ON M5R 2H3

CLAIM

DEFINITIONS

1. In this Statement of Claim, in addition to terms defined elsewhere herein, the following definitions apply:

- (a) “*Access to Cannabis for Medical Purposes Regulations*” means the *Access to Cannabis for Medical Purposes Regulations*, SOR/2016-230, as amended, repealed October 17, 2019;
- (b) “*Cannabis Act*” means the *Cannabis Act*, SC 2018, c 16 and accompanying regulations, all as amended, which came into force October 17, 2019;
- (c) “**CannTrust**” means the **Defendant**, CannTrust Holdings Inc.;
- (d) “**CEO**” means Chief Executive Officer;
- (e) “**CFO**” means Chief Financial Officer;
- (f) “*CJA*” means the *Courts of Justice Act*, RSO 1990, c C-43, as amended;
- (g) “**Core Documents**” means:
 - (i) **CannTrust’s MD&A** for the quarter ended June 30, 2018, filed on **SEDAR** August 14, 2018;
 - (ii) **CannTrust’s** interim financial statements for the quarter ended June 30, 2018, filed on **SEDAR** August 14, 2018;
 - (iii) the **CEO** and **CFO** certifications of the filings for the quarter ended June 30, 2018, filed on **SEDAR** August 14, 2018;
- (h) “*CPA*” means the *Class Proceedings Act, 1992*, SO 1992, c 6, as amended;

- (i) **“Defendants”** means, collectively, **CannTrust** and the **Individual Defendants**;
- (j) **“First Corrective Disclosure”** means **CannTrust’s** press release filed on **SEDAR** July 8, 2019 entitled “CannTrust Statement Regarding Health Canada Audit”;
- (k) **“Forum Financial”** means Forum Financial Corporation;
- (l) **“Gimelshtein”** means the Plaintiff Igor Gimelshtein;
- (m) **“IFRS”** means International Financial Reporting Standards;
- (n) **“Impugned Documents”** means the **Core Documents** and **Non-Core Documents**;
- (o) **“Individual Defendants”** means, collectively, Peter Aceto, Eric Paul, Ian Abramowitz, Mitchell Sanders, Mark Litwin, Fred Litwin, Robert Marcovitch, Mark Dawber, John Kaden, Shawna Page, and Brad Rogers;
- (p) **“MD&A”** means management’s discussion and analysis;
- (q) **“Niagara Facility”** means **CannTrust’s** cannabis cultivation facility (referred to as a “perpetual harvest facility”) located in Pelham, Ontario;
- (r) **“Non-Core Documents”** means:
 - (i) a press release filed on **SEDAR** August 14, 2018 by **CannTrust** entitled “CannTrust Reports Record Revenue for Q2 2018 and is on Track to Full Completion of its Million SQ FT Niagara Facility”;

- (ii) a press release filed on **SEDAR** August 21, 2018 by **CannTrust** entitled “CannTrust Announces Partnership with the Ontario Cannabis Retail Corporation to Supply a Wide Range of Recreational Products”;
- (iii) a press release filed on **SEDAR** September 10, 2018 by **CannTrust** entitled “CannTrust and Breakthru Beverage Enter Exclusive Partnership in Recreational Cannabis Market in Canada”;
- (iv) a press released filed on **SEDAR** September 13, 2018 by **CannTrust** entitled “CannTrust Recreational Cannabis Brands Achieve Distribution Across Canada”;
- (v) a press release filed on **SEDAR** September 18, 2019 by **CannTrust** entitled “CannTrust Makes History with First Shipment of Cannabis Oil to Danish Partner, STENOCARE”;
- (a) “**OBCA**” means the *Business Corporations Act*, RSO 1990, c B.16, as amended;
- (b) “**OSA**” means the *Securities Act*, RSO 1990, c S.5, as amended;
- (c) “**Phase 1 Expansion**” means the initial 250,000 square feet development of **CannTrust’s Niagara Facility** for cannabis cultivation;
- (d) “**Phase 2 Expansion**” means the 180,000 square feet expansion at **CannTrust’s Niagara Facility** for the cultivation of 25,000 kg of cannabis per/annum;
- (e) “**Second Corrective Disclosure**” means *The Globe & Mail* article dated July 23, 2019 entitled “CannTrust chairman, CEO were informed in November of unlicensed cannabis growing, e-mails show”;

- (f) “**SEDAR**” means the system for electronic document analysis and retrieval of the Canadian Securities Administrators;
- (g) “**Third Corrective Disclosure**” means **CannTrust**’s press release filed on **SEDAR** September 18, 2019 and issued on September 17, 2019 entitled “CannTrust Discloses Notice of Licence Suspension”;
- (h) “**TSX**” means the Toronto Stock Exchange;
- (i) “**Vaughan Facility**” means **CannTrust**’s cannabis processing facility in Vaughan, Ontario, which was formerly a cultivation facility; and
- (j) “**Zola**” means the Plaintiff Zola Finance Holdings Ltd.

RELIEF SOUGHT

2. The Plaintiffs claim:

- (a) an order granting leave to pursue this action under Part XXIII.1 of the *OSA*;
- (b) a declaration that the Impugned Documents contained one or more misrepresentations at common law and within the meaning of the *OSA*;
- (c) a declaration that the Defendants or one of them made the misrepresentations;
- (d) a declaration that the Defendants or one of them failed to make timely disclosure of a material change in the business, operations or capital of CannTrust;
- (e) a declaration under section 248 of the *OBCA* that:
 - (i) the acts and omissions of CannTrust and/or its affiliates have effected a result; or

(ii) the business and affairs of CannTrust and/or its affiliates have been carried on or conducted in a manner; or

(iii) the powers of the directors and/or officers of CannTrust and/or its affiliates have been exercised in a manner;

that is oppressive or unfairly prejudicial to or that unfairly disregards the interests of the Plaintiff;

- (f) a declaration that the Fred Litwin engaged in insider trading contrary to sections 74 and 134 of the *OSA*;
- (g) a declaration that CannTrust is vicariously liable for the acts and/or omissions of the Individual Defendants and, as may be applicable, of its other officers, directors, employees or agents;
- (h) rescission of some or all of Zola's acquisitions of CannTrust securities as pleaded herein;
- (i) general damages and/or compensation for oppression, in the sum of \$45,000,000 or such other relief as this Honourable Court deems just;
- (j) punitive damages, exemplary damages and/or aggravated damages in the amount of \$15,000,000;
- (k) prejudgment and post judgment interest;
- (l) costs of this action on a substantial indemnity basis or in an amount that provides full indemnity; and
- (m) such further and other relief as this Honourable Court may deem just.

OVERVIEW

3. This action arises out of the Plaintiffs' joint investment in CannTrust, which was made after CannTrust had decided to cultivate cannabis illegally, had taken the necessary steps to set up the illegal cultivation operations, had commenced illegal cultivation and had begun to illegally store cannabis.
4. None of these critically important facts were disclosed to the Plaintiffs or their representatives before they became one of CannTrust's largest shareholders, even though many of the company's senior directors and officers, including CFO Abramowitz and founder and then-CEO Paul, were aware of this illegal behaviour.
5. In addition, prior to making its investment, a principal of Zola, Tarik Ouass, and Gimelshtein spoke with Fred Litwin, a large shareholder of CannTrust who sold the Plaintiffs 1 million shares of CannTrust (with a market value of \$12.67 million at the time) at the peak of CannTrust's share price, even as CannTrust was proceeding with its scheme to illegally cultivate and sell cannabis and was illegally storing cannabis. They also spoke with Eric Paul, CannTrust's founder, then-CEO and future Chairman, before purchasing the shares from Fred Litwin.
6. In order to entice the Plaintiffs to invest in CannTrust, Fred Litwin and Paul touted the company as well positioned for future growth while failing to disclose the illegal scheme that they knew or ought to have known was underway and the illegal storage of cannabis that was already occurring. Fred Litwin knew or ought to have known the truth because the company he controlled, Forum Financial, had been party to a management service agreement with CannTrust to aid CannTrust with its continuous disclosure obligations and reporting obligations. Fred Litwin's son Mark Litwin was and is a member of

CannTrust's board. As CannTrust's founder and then-CEO, Paul was well aware of CannTrust's illegal cultivation operations and illegal storage of cannabis.

7. CannTrust's public disclosures also significantly misrepresented the company's state of affairs. They failed to disclose CannTrust's illegal behaviour and heavily promoted CannTrust's future growth potential based on recreational cannabis legalization (which occurred on October 17, 2018) and the lucrative market for future cannabis sales this would create. Indeed, CannTrust invested heavily in its cultivation and processing capacity to position itself favourably for recreational cannabis legalization.
8. The foundational requirement for CannTrust's ability to capitalize on recreational cannabis legalization was the maintenance of its Health Canada license to cultivate, process and sell cannabis legally.
9. Without a license, CannTrust is virtually worthless—it would have no legal business and no ability to raise capital to sustain its operations. The Plaintiffs, who have extensive operational experience in the legal cannabis industry, understood this and did careful due diligence both before and after they invested to ensure that the company was in compliance with Health Canada regulations. This due diligence included frequent communications with Paul and CEO Aceto.
10. In both individual communications and in the public disclosures, the Defendants actively misled the Plaintiffs, making explicit and/or implicit representations that CannTrust was and would continue cultivating, processing, storing and selling cannabis according to the requirements of the *Cannabis Act* and/or its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*. This was not true.

11. The Defendants also represented that CannTrust had reasonably effective internal control over financial reporting (“**ICFR**”) and disclosure controls and procedures (“**DC&P**”). CannTrust did not.
12. Beginning on or around June 1, 2018, CannTrust began storing cannabis in five rooms in the Vaughan Facility without the authorization required by Health Canada. As of November 2018, CannTrust had constructed two new areas in the Vaughan Facility and stored cannabis in those areas without the required authorization of Health Canada.
13. On or around September 1, 2018, CannTrust made the decision to cultivate cannabis in unlicensed rooms in the Phase 2 Expansion of the Niagara Facility, process that cannabis and sell it. Following this decision, CannTrust undertook the necessary steps to facilitate the illegal cultivation of cannabis in the Phase 2 Expansion. Starting in late September and continuing until on or around April 8, 2019, CannTrust cultivated cannabis in five rooms in its Phase 2 Expansion in the Niagara Facility that had not been licensed by Health Canada for cannabis cultivation.
14. CannTrust also used cannabis seeds at the Niagara Facility that were obtained from the black market starting in 2018. CannTrust cultivated over 1000 cannabis plants from the black-market cannabis seeds, mislabelled those seeds under its authorized cannabis strains and sold them into the recreational market.
15. The above conduct was illegal under the *Cannabis Act* and its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*. The illegal conduct jeopardized CannTrust’s key asset—its license to cultivate, process and sell cannabis, which was subject to revocation or suspension for conduct contrary to the *Cannabis Act* or the *Access to Cannabis for Medical Purposes Regulations*. CannTrust also illegally exported

the unlicensed cannabis to foreign countries, including Denmark, in violation of the international narcotics treaties and domestic criminal law. CannTrust's senior management and, at least some board members were fully aware of and directed all of this illegal conduct.

16. The truth about CannTrust's non-compliance with applicable laws and regulations was revealed via three corrective disclosures.
17. The First Corrective Disclosure was a press release issued by CannTrust on July 8, 2019 that revealed certain of CannTrust's illegal conduct. CannTrust disclosed that cannabis had been illegally grown in five unlicensed rooms in the Phase 2 Expansion of its Niagara Facility from October 2018 to March 2019 and that inaccurate information had been provided by CannTrust employees to Health Canada. CannTrust disclosed that Health Canada had made a finding of non-compliance related to these activities and that it had accepted the non-compliance finding. CannTrust also disclosed that it had advised Health Canada of cannabis storage compliance issues at its Vaughan Facility. As a consequence of the illegal conduct, Health Canada placed a hold on 5,200 kg of dried cannabis harvested from the unlicensed rooms while it continued its investigation. CannTrust put a voluntary hold on an additional 7,500 kg of dried cannabis stored at its Vaughan Facility. The cannabis put on hold was worth between \$51,000,000 and \$77,000,000.
18. As a result of the First Corrective Disclosure, CannTrust's share price declined materially on abnormally high trading volumes from C\$6.46 at the close of trading on July 5, 2019 to C\$5.00 at the close of trading on July 8, 2019 and down to C\$3.34 at the close of trading on July 12, 2018.

19. The Plaintiffs' losses were compounded by a conversation that Gimelshtein had with CannTrust CEO Eric Paul on the day of the First Corrective Disclosure. During the conversation Paul misled Gimelshtein, advising him that that he had not been aware of the illegal cannabis growing until the news on October 8, 2019 broke, something that has been proven to be untrue. Paul also assured Ouass and Gimelshtein that the issue did not extend into the highest levels of CannTrust's management team. He maintained that the company was well-positioned for future growth. Gimelshtein and Zola relied on these representations and did not sell their CannTrust shares, suffering further losses as a result.
20. Subsequent disclosures indicated that Health Canada had become aware of CannTrust's illegal cannabis operations from a whistleblower who had formerly worked at the Niagara Facility. The whistleblower disclosed that on at least one occasion he and other employees had been asked to set up fake walls to conceal cannabis cultivation in one of the unlicensed rooms in compliance pictures sent to Health Canada. In the wake of these and other revelations, CannTrust announced a voluntary hold on the sale and shipment of all cannabis products and the formation of a special committee to investigate.
21. Health Canada also investigated the cannabis storage compliance issues at the Vaughan Facility revealed by CannTrust in the First Corrective Disclosure and made findings of non-compliance that CannTrust accepted. The two key non-compliance issues were:
 - (a) the conversion of five rooms in the Vaughan Facility to cannabis storage areas and the storage of cannabis in those areas since June 2018 without required Health Canada approval; and
 - (b) the construction of two new areas at the Vaughan Facility that were used for cannabis storage starting in November 2018 without Health Canada approval.

22. The Second Corrective Disclosure revealed that the illegal conduct had occurred with the knowledge and at the direction of senior management and, at least some, members of the board. Aceto (CEO), Abramowitz (CFO) and Paul (founder, Chairman and former CEO), had knowledge of ongoing illegal cannabis cultivation in unlicensed rooms in the Phase 2 Expansion and plans for additional illegal cultivation in unlicensed rooms in the future. This was further confirmed by the publication of excerpts of minutes of CannTrust meetings in a *Business News Network* article and other internal emails leaked to the press. Aceto was subsequently fired as CEO and Paul was forced to resign as Chairman.
23. As a result of the Second Corrective Disclosure, there was a material decline in CannTrust's share price on abnormally high trading levels from C\$3.43 per share at the close of trading on July 23, 2019 to C\$2.68 per share at the close of trading on July 24, 2019.
24. Following the Second Corrective Disclosure, a joint Ontario Securities Commission ("OSC"), Ontario Provincial Police and Royal Canadian Mounted Police investigation, a delay in the filing of CannTrust's second quarter results for 2019 and the withdrawal of KPMG LLP's previous audit opinions were announced. It was also disclosed that CannTrust had been using black market cannabis seeds in its cannabis cultivation operations at the Niagara Facility.
25. The Third Corrective Disclosure revealed that CannTrust had received a notice of license suspension under section 64 of the *Cannabis Act* from Health Canada. CannTrust disclosed that Health Canada suspended CannTrust's authority to produce and sell cannabis, other than cultivating and harvesting existing lots or batches of cannabis.

26. As a result of the Third Corrective Disclosure, there was a material decline in CannTrust's share price on abnormally high trading levels from C\$1.99 per share at the close of trading on September 16, 2019 to \$1.70 per share at the close trading on September 17, 2019.
27. While the Defendants were disseminating misrepresentations to the market, CannTrust insiders—including Fred Litwin—took advantage of their knowledge of undisclosed material facts and changes to profit, or to obtain a profit for their family members. Insiders sold shares or directed the sale of shares on the secondary market and to the Plaintiffs and others at substantially higher prices than the post-corrective disclosure CannTrust share price.
28. As a result of the Defendants' misrepresentations, their improper financial reporting and disclosures, and other actionable misconduct described herein, the Plaintiffs have incurred significant losses and damages on its investment in CannTrust securities.

THE PARTIES

The Plaintiffs

29. The Plaintiff Zola is a duly formed private corporation.
30. Zola is an operationally focused investment fund that concentrates on investments in the legal cannabis industry.
31. The Plaintiff Gimelshtein is a resident of Toronto, Ontario. He is an investor focused on investments in the legal cannabis industry. He works closely with Zola and served as its agent for the purposes of their joint investment in CannTrust throughout the relevant time.

32. Both Zola and Gimelshtein have extensive experience in the legal cannabis industry. Gimelshtein is former Chief Financial Officer of cannabis company MedReleaf Corp., which was purchased by a large Canadian cannabis company in 2018. Zola's principal, Tarik Ouass, was one of the largest investors in MedReleaf Corp. until its sale.
33. Since late September 2018, Zola and Gimelshtein have been one of CannTrust's larger shareholders. Zola, on behalf of itself and Gimelshtein, purchased 1 million CannTrust shares from Fred Litwin or a corporation wholly or partially owned or controlled by Fred Litwin on September 25, 2018. The share purchase transaction with Fred Litwin was by way of a neutral counterparty and the Plaintiffs do not know the identity of the entity that sold the 1 million shares, though they know the entity is controlled, beneficially owned and/or connected to Fred Litwin.
34. Zola, on behalf of itself and Gimelshtein, then purchased an additional 2 million CannTrust shares between September 26-28, 2018 over the TSX.
35. Zola held 15% percent of the shares purchased in trust for Gimelshtein. It held 85% of the shares purchased for its own benefit.
36. Zola and Gimelshtein would not have made an investment in CannTrust had it known about CannTrust's material non-compliance with the *Access to Cannabis for Medical Purposes Regulations* and *Cannabis Act*.

The Defendants and their Disclosure Obligations

CannTrust

37. CannTrust is a company incorporated under the *OBCA*.

38. At all material times, CannTrust was a reporting issuer in all Canadian provinces besides Québec.
39. At all material times, CannTrust's common shares were listed for trading on the TSX under the ticker symbol "TRST". Since February 25, 2019, CannTrust common shares have been listed for trading on the New York Stock Exchange under the ticker symbol "CTST". CannTrust's common shares are also listed for trading on alternative trading venues in Canada and elsewhere.

The Individual Defendants

40. Eric Paul is the former CEO and Chairman of CannTrust. He is also the co-founder of CannTrust. Paul served as CEO of CannTrust until October 1, 2018 when he was replaced by Aceto. After Paul stepped down as CEO, he was appointed as Chairman of CannTrust's board and as a Special Advisor to CannTrust's management team. Paul was forced to resign as Chairman on or around July 25, 2019.
41. Peter Aceto was appointed as CEO of CannTrust on October 1, 2018. Aceto's termination for cause was announced on July 25, 2019.
42. Ian Abramowitz was CannTrust's CFO until February 19, 2019. Since that time, he has acted as CannTrust's Senior-Vice President of Global Investments and Partnerships.
43. Mark Litwin is an independent director and Vice-Chairman of the board of CannTrust. Mark Litwin was the Chairman of CannTrust until Paul was appointed to that position on October 1, 2019. He is the son of the Defendant Fred Litwin.
44. Mitchell Sanders is a director of CannTrust. Sanders provided legal services to CannTrust through his firm Goldman, Spring, Kichler & Sanders LLP.

45. John Kaden was an independent director of CannTrust. He was appointed to that position effective October 22, 2018. Kaden resignation from his directorship was announced October 28, 2019.
46. Mark Dawber is an independent director of CannTrust.
47. Robert Marcovitch was an independent director of CannTrust. He was appointed CannTrust's interim CEO after Aceto's termination.
48. Shawna Page is an independent director of CannTrust.
49. Brad Rogers was President of CannTrust until on or around November 12, 2018.
50. Fred Litwin has significant CannTrust share holdings. He also owned, controlled and is Chairman of Forum Financial, which had a management services agreement with CannTrust. Stan Abramowitz, the secretary to CannTrust's board, is the CFO of Forum Financial. Mark Litwin is the President of Forum Financial

THE DEFENDANTS' DISCLOSURE OBLIGATIONS

CannTrust's Disclosure Obligations

51. At all material times, CannTrust was, by its own election, a reporting issuer in every Canadian province besides Québec. It elected to become a reporting issuer in order to render its securities publicly tradable. Doing so made them a more attractive investment and provided CannTrust with broader access to capital.
52. In order to maintain its status as a reporting issuer, CannTrust was required to release and file on SEDAR:
 - (a) within 45 days of the end of each quarter, quarterly financial statements prepared in accordance with applicable accounting principles that must include a

comparative statement to the end of each of the corresponding periods in the previous financial year;

- (b) within 90 days of the end of the fiscal year, annual financial statements prepared in accordance with IFRS, including comparative financial statements relating to the period covered by the preceding financial year;
 - (c) contemporaneously with each of the above, MD&A for each of the above financial statements; and
 - (d) within 90 days of the end of the fiscal year, an Annual Information Form.
53. MD&As are a narrative explanation of how the company performed during the period covered by the financial statements, and of the company's financial condition and future prospects. The MD&A must discuss known trends, events and risks that have affected the financial statements of the issuer, or that are reasonably likely to have an effect on the issuer's business in the future.
54. In fulfilling the above requirements and in making disclosures to the market generally, CannTrust was prohibited from making a statement that:
- (a) in a material respect and at the time and in the light of the circumstances under which it was made, was misleading or untrue or did not state a fact that was required to be stated or that was necessary to make the statement not misleading; and
 - (b) would reasonably be expected to have a significant effect on the market price or value of its securities.

55. CannTrust controlled the contents of the MD&As, financial statements, and the other documents particularized herein, and the misrepresentations made therein were made by CannTrust.
56. CannTrust was also required to immediately disclose (via press release) all changes in its business, operations or capital that would reasonably be expected to have a significant effect on the market price or value of its securities. Pursuant to NI 51-102, CannTrust was required to file a material change report on SEDAR as soon as practicable or in any event within 10 days after the occurrence of the material change.
57. CannTrust knew and intended that both current shareholders and prospective investors would rely on its disclosure in making decisions to purchase and sell securities issued by CannTrust.

The Individual Defendants' Role in CannTrust's Disclosure

58. Each of the Individual Defendants, from the time that he or she accepted a position as a director and/or officer of CannTrust, knew that CannTrust was a reporting issuer and that, in his or her role as a director and/or officer of CannTrust, he or she would have responsibility for ensuring the accuracy of CannTrust's disclosure documents. Further, each of the Individual Defendants knew and intended that both current shareholders and prospective investors would rely on CannTrust's disclosure in making decisions to purchase and sell securities issued by CannTrust.
59. The *OSA*, certain instruments and policies promulgated thereunder, and CannTrust's own internal policies imposed specific personal obligations on the Individual Defendants in the preparation of CannTrust's disclosure documents.

60. NI 51-102 requires the board of directors' prior approval of financial statements and MD&A. As such, the Defendants Paul, Mark Litwin, Sanders, Dawber, Marcovitch, Page, and Kaden, each of whom was a director of CannTrust, were required to review and approve each set of financial statements and related MD&A prior to their release.
61. Moreover, the mandate of CannTrust's board was "to provide oversight for the Corporation and to act honestly and in good faith with a view to its best interests". With respect to risk monitoring, compliance and corporate performance, the members of the Board were specifically required to:
- a) Assess and monitor the principal risks of all aspects of the businesses in which the Corporation and its subsidiaries as a whole are engaged.
 - b) Monitor performance of the Corporation and its subsidiaries against both short-term and long-term strategic plans and annual performance targets, and monitor compliance with Board policies and the effectiveness of risk management practices.
 - c) Verify that the Corporation has implemented and maintains adequate and effective internal controls and management information systems which ensure the directors discharge the Board's oversight responsibilities, including the Corporation's compliance with legal and regulatory requirements related to financial and other continuous disclosure reporting.
- [emphasis added]
62. Mark Litwin, Dawber, Marcovitch and Kaden were each members of CannTrust's Audit Committee. The Audit Committee charter required them to review the financial statements, press releases containing financial information and guidance, and disclosures made to the CEO and CFO during the certification process. The charter also made them responsible for oversight of internal controls and procedures, disclosure controls, risk assessment and management, and for CannTrust's internal audit function.
63. Pursuant to NI 52-109 and the Companion Policy thereto, the Defendants Paul, Aceto and Abramowitz as CannTrust's CEO and CFOs, respectively, were responsible for designing

CannTrust's ICFR and DC&P and they were required to certify that they had done so when they were in their respective positions. NI 52-109 also required them to certify the accuracy of CannTrust's annual and interim financial statements and related MD&As and CannTrust's annual information form released.

64. Each Individual Defendant was aware of and accepted these obligations, as applicable, in assuming his or her position as a director and/or officer of CannTrust.

Fred Litwin and Forum Financial

65. In late 2016, Forum Financial entered into a management services agreement with CannTrust to "assist it with its continuous disclosure and reporting requirements". As such Forum Financial, and Fred Litwin as its directing mind, undertook to assist CannTrust in providing disclosures in accordance with the *OSA*.
66. Forum Financial's management services agreement with CannTrust ended on March 31, 2019.

BACKGROUND

Canada's Nascent Cannabis Industry

67. At the time of the Plaintiffs' acquisition of CannTrust shares, the cultivation, processing, and sale of cannabis was regulated by the *Access to Cannabis for Medical Purposes Regulation*. The *Access to Cannabis for Medical Purposes Regulation* only permitted the sale of cannabis to the limited medicinal market.
68. The *Cannabis Act* was scheduled to replace the *Access to Cannabis for Medical Purposes Regulation* on October 17, 2018. The *Cannabis Act* legalized the cultivation, processing and sale of cannabis for the lucrative retail market in Canada. Licenses granted under the

Access to Cannabis for Medical Purposes Regulation for the cultivation of cannabis, such as those held by CannTrust, would continue under the *Cannabis Act* with similar (but not identical) requirements and limitations.

69. CannTrust heavily touted its future growth potential based on recreational cannabis legalization and the lucrative market for future cannabis sales this would create. Indeed, CannTrust had invested heavily in its cultivation and processing capacity to position itself favourably for recreational cannabis legalization, including by purchasing and refurbishing the Niagara Facility for cannabis cultivation. However, the foundational requirement for CannTrust's ability to capitalize on recreational cannabis legalization was the maintenance of its Health Canada license to cultivate, process, store and sell cannabis legally.
70. Therefore, the most critical determinant of CannTrust's success at the time of the Plaintiffs' CannTrust share acquisitions was its license to cultivate, process, store and sell cannabis and its ability to maintain that license. Without a license, CannTrust was virtually worthless—it would have no business and no ability to raise capital to sustain its operations. With a license CannTrust was set up for future profitability and growth.

CannTrust's Operations and Expansion: The Vaughan Facility and Niagara Facility

71. CannTrust cultivates cannabis and processes, stores and sells that cannabis. CannTrust conducts these business operations through its wholly owned subsidiary CannTrust Inc.
72. CannTrust's business operations were originally conducted out of the Vaughan Facility. That Facility had limited cannabis cultivation capacity. To meet the growing demand in the medicinal cannabis market, and in anticipation of the legalization of cannabis for recreational use, CannTrust purchased the Niagara Facility.

73. The Vaughan Facility was turned into a cannabis processing facility sometime after cultivation started at the Niagara Facility. CannTrust began illegally storing cannabis in five rooms in the Vaughan Facility starting on or around June 1, 2018. CannTrust constructed two additional areas in the Vaughan Facility and began illegally storing cannabis in those areas in November 2018.
74. The Niagara Facility was not designed or licensed to cultivate cannabis in accordance with regulatory requirements when it was acquired. CannTrust developed the Niagara Facility into a commercial cannabis cultivation facility in phases. The Phase 1 Expansion involved the development of 250,000 square feet of the Niagara Facility. A Health Canada cultivation license for the Phase 1 Expansion was granted in October 2017 under the predecessor legislation to the *Cannabis Act*, the *Access to Cannabis for Medical Purposes Regulations*. Work on the five-room, 180,000-square-foot Phase 2 Expansion then commenced. The combined growing capacity for both the Phase 1 and Phase 2 Expansions was 50,000 kg per/annum, with the Phase 2 Expansion contributing half the capacity.
75. The Phase 2 Expansion was initially scheduled to be completed and in production by mid-2018. However, at the start of September 2018, as the demand for cannabis was about to skyrocket due to the upcoming legalization of recreational cannabis use on October 17, 2018, CannTrust was facing shortages its cannabis supply, the Phase 2 Expansion had not yet been licensed for cultivation of cannabis.
76. Despite this, on or about September 1, 2018, CannTrust decided to illegally cultivate cannabis in the Phase 2 Expansion of the Niagara Facility. Following this decision, CannTrust took the necessary operational steps to cultivate cannabis in the unlicensed

rooms. CannTrust's illegal cultivation of cannabis in completed Phase 2 Expansion rooms began sometime in September 2018. The exact start date of cultivation is solely within the Defendants' knowledge. However, CannTrust started illegal cannabis cultivation in a room in the Phase 2 Expansion referred to internally as "RG8". In November 2018, CannTrust began illegal cultivation in the unlicensed 50,000- square-foot room in the Phase 2 Expansion referred to as "RG9".

77. CannTrust also cultivated illegal cannabis in other Phase 2 Expansion rooms. By at least February 26, 2019, CannTrust was illegally cultivating cannabis in all five rooms in the Phase 2 Expansion. CannTrust's illegal cultivation continued until those rooms were licensed by Health Canada in or around April 8, 2019.
78. While CannTrust was illegally cultivating cannabis in the Phase 2 Expansion rooms, it also illegally obtained cannabis seeds on the black market and cultivated those cannabis seeds. CannTrust disguised the cannabis it grew from the black market seeds as strains of its approved cannabis and illegally sold that cannabis to recreational users.

MISREPRESENTATIONS

79. As further particularized below, the Defendants made the following explicit or implicit representations in their public disclosures, which the Plaintiffs relied on when making the decision to invest in CannTrust:
- (a) that CannTrust was complying and would continue to comply with the licensing requirements for the cultivation, processing, storage and sale of cannabis under the *Cannabis Act* and its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*, including with respect to the cultivation of

cannabis in the Phase 2 Expansion of the Niagara Facility and the storage of cannabis in the Vaughan Facility;

- (b) that CannTrust and its employees were forthright with Health Canada and did not actively try to mislead Health Canada;
- (c) that CannTrust had accurately reported financial and cannabis production guidance for fiscal year 2019; and
- (d) that CannTrust had reasonably effective ICFR and DC&P, including with respect to CannTrust's compliance with the *Cannabis Act* and its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*.

80. These implicit and explicit representations were materially misleading.

81. The First, Second and Third Corrective Disclosures revealed that CannTrust violated the *Cannabis Act* and its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*. With the knowledge and at the direction of senior management and, at least some, members of the board:

- (a) starting on or around June 1, 2018, CannTrust illegally stored cannabis in five rooms in the Vaughan Facility without the required authorization from Health Canada. CannTrust also constructed two new areas in the Vaughan Facility and began storing cannabis in those areas without the requisite Health Canada approval by November of 2018; and
- (b) at least as of September 1, 2018, CannTrust had decided to and was taking preparatory steps to illegally cultivate cannabis in the Phase 2 Expansion of the Niagara Facility, process and store that cannabis and sell it. CannTrust then took

the operational steps necessary to illegally cultivate cannabis in the Phase 2 Expansion and, in fact, illegally cultivated cannabis, processed, stored and sold it. CannTrust's illegal cultivation of cannabis continued until April 8, 2019, and CannTrust's processing and sale of that illegally cultivated cannabis continued to on or about the First Corrective Disclosure.

While this was occurring, CannTrust actively misled Health Canada about its illegal conduct. Among other things, CannTrust sent deceptive photos that used false walls to hide its production of cannabis in unlicensed rooms from Health Canada

82. Further, CannTrust's ICFR and DC&P were not effective as a result of material weaknesses in their design and operating effectiveness, resulting in ineffective controls over compliance and non-compliance with the *Cannabis Act* and its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*.
83. CannTrust's misconduct resulted in material risks to CannTrust's business and operations that were undisclosed or not adequately disclosed to the Plaintiffs, including:
 - (a) criminal and/or regulatory enforcement actions and penalties, including, Health Canada placing a hold on sales of illegally cultivated or stored cannabis, a Health Canada suspension or revocation of CannTrust Inc.'s cannabis licenses, Health Canada fines, criminal prosecution of CannTrust and its senior management for violations of the *Cannabis Act* and/or its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*, OSC enforcement actions and fines, SEC enforcement actions and potential fines and potential enforcement action from a domestic or foreign law enforcement or regulatory agency relating to CannTrust's exporting of cannabis to foreign countries;

- (b) an inability to secure future licenses, including for its outdoor cultivation facility in British Columbia;
- (c) loss of clients and distribution channels, including CannTrust's medicinal cannabis clientele, Canadian provincial cannabis distributors such as the Ontario Cannabis Store, international clients and its joint venture partner, Stenocare A/S (“**Stenocare**”);
- (d) a material decline or lack of growth in cannabis cultivation, sales and revenue; and
- (e) severe reputational damage.

Misrepresentations in CannTrust's Continuous Disclosure Documents

84. CannTrust made the misrepresentations in the Impugned Documents described below. In August and September 2018, as part of its comprehensive review of CannTrust as a potential investment, the Plaintiffs reviewed and relied on these misrepresentations when making the decision to acquire CannTrust shares.
85. On August 14, 2018, CannTrust filed its interim financial statements and MD&A for the quarter ended June 30, 2018 on SEDAR. In the MD&A, CannTrust stated that the Vaughan Facility was a “state-of-the-art hydroponic indoor facility” and that CannTrust’s “primary focus is to produce and deliver the highest quality, standardized, pharmaceutical grade cannabis products and in so doing strengthen its market share in legal cannabis markets in Canada and to establish positions for its products in legal cannabis markets abroad.” These statements were materially misleading because they failed to disclose the illegal storage of cannabis in the Vaughan Facility. They were also materially misleading

due to their failure to disclose the risks posed by CannTrust's illegal conduct (as particularized at paragraph 83).

86. The MD&A incorporated by reference CannTrust's MD&A for the year ended December 31, 2017, filed on SEDAR March 29, 2018. That MD&A stated that CannTrust "believes that it is complying in all material respects with the terms of such licences and permits" under the *Access to Cannabis for Medical Purposes Regulations*. This statement was materially misleading. It failed to disclose that CannTrust was storing cannabis illegally at the Vaughan Facility contrary to the *Access to Cannabis for Medical Purposes Regulations*. As such, CannTrust did not believe it was complying with the terms of its licenses and permits, or alternatively, any such belief was not reasonably held.
87. The MD&A CannTrust filed on SEDAR for the quarter ended June 30, 2018 stated that CannTrust's DC&P was designed to provide reasonable assurance that material information relating to CannTrust is made known to senior management, including the CEO and CFO and that information required to be disclosed by CannTrust is recorded, processed, summarized and reported within the time periods specified in securities legislation. CannTrust further disclosed that ICFR is designed by management, under the supervision of the CEO and CFO, to provide reasonable assurance regarding the reliability of the CannTrust's financial reporting and the preparation of its financial statements in accordance with IFRS.
88. These statements were materially false and/or misleading in that CannTrust's ICFR and DC&P were not then effective, and were not effective at any relevant time, as a result of material weaknesses in the design and operating effectiveness of ICFR and DC&P relating to ineffective controls over compliance and non-compliance with the *Access to*

Cannabis for Medical Purposes Regulations and later the *Cannabis Act* and the disclosure of that non-compliance as alleged herein.

89. CannTrust's CEO and CFO provided certifications along with the periodic disclosures for the quarter ended June 30, 2018. Those certifications stated that

- (a) the periodic disclosure documents did not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made;
- (b) the CEO and CFO were responsible for establishing and maintaining DC&P and ICFR;
- (c) the CEO and CFO had designed DC&P, or caused it to be designed under their supervision, to provide reasonable assurance that material information relating to CannTrust was made known to them by others, particularly during the period in which the documents were being prepared, and information required to be disclosed by CannTrust in its annual filings, interim filings or other reports filed or submitted under securities legislation was recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- (d) the CEO and CFO had designed ICFR, or caused it to be designed under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

90. As particularized herein, the CannTrust disclosure documents contained misrepresentations. Paul and Abramowitz at the time they made their respective certifications, knew or ought to have known this to be the case and in particular they knew, ought to have known or were wilfully blind to the fact that, they had not designed DC&P, or caused it to be designed under their supervision, to provide reasonable assurance that information required to be disclosed by CannTrust in its annual filings, interim filings or other reports filed or submitted under securities legislation was recorded, processed, summarized and reported within the time periods specified in securities legislation, and that they had not designed ICFR, or caused it to be designed under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. Accordingly, the Certifications given were false and themselves misrepresentations.
91. On August 14, 2018, CannTrust issued a press release on SEDAR entitled “CannTrust Reports Record Revenue for Q2 2018 and is on Track to Full Completion of its Million SQ FT Niagara Facility.” In that press release Paul (then CEO) stated that “[w]e continued to experience dynamic growth in all areas of the Company as we execute our business plan aimed at being a market leader and innovator in the development of products and services to better serve our patients and physicians and to position us for the October 17th legalization of the adult use recreational market.” Brad Rogers (then president) stated that “[w]ith Bill C-45 receiving Royal Assent legalizing cannabis for adult consumer use on October 17, 2018, our Perpetual Harvest Facility [the Niagara Facility] offers CannTrust even more opportunities to lead the industry with its disciplined, scientific approach.” These statements were materially misleading. Both

Rogers and Paul omitted the material risks that CannTrust's non-compliance with *Access to Cannabis for Medical Purposes Regulations* and planned non-compliance with the *Cannabis Act* posed to CannTrust's ability to capitalize on the legalization of recreational cannabis.

92. On August 21, 2018, CannTrust issued a press release on SEDAR entitled "CannTrust Announces Partnership with the Ontario Cannabis Retail Corporation to Supply a Wide Range of Recreational Products." In the press release CannTrust stated that "[b]eginning October 17, 2018, consumers will be able to purchase CannTrust's quality, standardized cannabis via an online retail platform provided by the OCS in a variety of formats. The agreement positions the company for rapid growth in the largest consumer market in Canada and expands on the Company's existing partnerships with provinces across the country, with more being finalized." This statement was materially misleading because it failed to disclose that CannTrust was illegally storing cannabis in its Vaughn Facility. The statement was also materially misleading because it failed to disclose the material risks (particularized at paragraph 83 above) to CannTrust's ongoing operations and future growth from its illegal conduct.
93. On September 10, 2018, CannTrust issued a press release on SEDAR entitled "CannTrust and Breakthru Beverage Enter Exclusive Partnership in Recreational Cannabis Market in Canada". CannTrust stated that it was a "federally regulated licensed producer" and that the Phase 2 Expansion of the Niagara Facility "is expected to be operational in the third quarter." These statements were materially misleading. CannTrust failed to disclose that it had decided and was taking preparatory steps to illegally cultivate cannabis in the Phase 2 Expansion of the Niagara Facility. CannTrust failed to disclose that it was illegally storing cannabis in the Vaughn Facility. CannTrust also failed to disclose the

material risks (particularized at paragraph 83 above) to its cannabis licenses and operations that arose from its illegal conduct.

94. On September 13, 2018, CannTrust issued a press release on SEDAR entitled “CannTrust Recreational Cannabis Brands Achieve Distribution Across Canada.” CannTrust stated that it was “one of Canada’s leading licensed producers” and was “emerging as a leader within the adult-use recreational cannabis market.” CannTrust also stated that it had “a long-term strategy to be a market share leader in the Canadian recreational space.” These statements were materially misleading. CannTrust failed to disclose that it had decided and was taking preparatory steps to illegally cultivate cannabis in the Phase 2 Expansion of the Niagara Facility. CannTrust further failed to disclose that it was illegally storing cannabis in the Vaughn Facility. CannTrust, therefore, failed to disclose the illegal underpinnings of its recreational cannabis strategy. CannTrust failed to disclose the material risks (particularized at paragraph 83 above) to its cannabis licenses and operations that arose from its illegal conduct. CannTrust also made the same misrepresentations as in paragraphs 79-80 above.
95. On September 18, 2018, CannTrust issued a press release on SEDAR entitled “CannTrust Makes History with First Shipment of Cannabis Oil to Danish Partner, STENOCARE”. In that press release CannTrust stated that it was one of Canada’s “most trusted licensed producers of cannabis.” CannTrust further stated that its shipment of cannabis oil to Stenocare was “the first phase of the STENOCARE strategy which is to import and distribute quality products from CannTrust” in Denmark. These statements were materially misleading. CannTrust failed to disclose that it had decided and planned to illegally cultivate cannabis in the Phase 2 expansion of the Niagara Facility, was taking or had taken the operational steps necessary to do so, and, in fact, had started illegally

cultivating cannabis. CannTrust further failed to disclose that it was illegally storing cannabis in the Vaughn Facility. CannTrust failed to disclose that the cannabis it planned to export to Stenocare would be illegally cultivated in the Phase 2 Expansion of the Niagara Facility. CannTrust also failed to disclose the material risks to its ability to supply Stenocare with cannabis posed by its illegal conduct, including the risk that the company would be found to be in violation of foreign or domestic laws for its exporting of illegally produced cannabis to foreign countries. CannTrust also made the same misrepresentations as in paragraphs 79-80 above.

96. Further or in the alternative, all the Impugned Documents were materially misleading because they omitted the material information described at paragraphs 81 above.

The Failure to Disclose a Material Change

97. CannTrust's illegal storage of cannabis in its Vaughan Facility was a change in its business, operations or capital that was required to be disclosed immediately upon its occurrence. CannTrust failed to do so.
98. CannTrust's decision to illegally cultivate cannabis in the Phase 2 Expansion of the Niagara Facility, the steps taken to facilitate the illegal cultivation of cannabis in the Phase 2 Expansion, the illegal cultivation of cannabis in the Phase 2 Expansion and the illegal exporting of cannabis to foreign countries were changes in CannTrust's business, operations or capital that were required to be disclosed immediately upon their occurrence. CannTrust failed to do so.
99. The material weaknesses in CannTrust's ICFR and DC&P's design and operating effectiveness, which resulted in ineffective controls over compliance and non-compliance with the *Cannabis Act* and its predecessor regulation the *Access to Cannabis for Medical*

Purposes Regulations, were material changes to CannTrust's business operations and capital that ought to have been disclosed immediately upon their occurrence. CannTrust failed to do so.

100. The material risks to CannTrust's business and operations that arose as a result of its misconduct as particularized at paragraph 83 above were material changes in CannTrust's business, operations or capital that should have been disclosed immediately. CannTrust failed to do so.

PRE AND POST PURCHASE INDIVIDUAL MISREPRESENTATIONS MADE TO THE PLAINTIFFS

Pre-Purchase Misrepresentations

101. Prior to making any investments in CannTrust Gimelshtein, acting on behalf of himself and Zola, spoke to Paul, CannTrust's founder and then-CEO, about CannTrust. At the time Zola was contemplating investing in CannTrust and in the course of these conversations, which took place in September 2018, Gimelshtein made specific inquiries about the state of CannTrust's licensing, as he understood that licensing was the single most critical component of a successful cannabis company.
102. Among other things, Gimelshtein asked specific questions about CannTrust's interactions with Health Canada, when CannTrust expected to receive the license for the Phase 2 Expansion and whether CannTrust had a plan in the event there was a delay in receiving the license for the expansion.
103. Paul, who knew or ought to have known that CannTrust had begun its scheme to illegally cultivate marijuana and who knew or ought to have known that CannTrust was illegally storing cannabis in the Vaughan Facility, provided misleading answers to Gimelshtein. He spoke positively about the likelihood that the company would receive its license for

the Phase 2 Expansion and generally touted the company's future prospects, while omitting to state that CannTrust had begun the process of illegally cultivating cannabis and was illegally storing cannabis, which would jeopardize CannTrust's license and ability to continue as a going concern. Paul omitted to state the material risks that CannTrust's non-compliance with *Access to Cannabis for Medical Purposes Regulations* and planned non-compliance with the *Cannabis Act* posed to CannTrust's ability to capitalize on the legalization of recreational cannabis.

104. The Plaintiffs relied on these representations and omissions when deciding to invest in CannTrust and suffered damages as a result. Zola and Gimelshtein would not have acquired any of their CannTrust shares had Paul disclosed CannTrust's illegal cultivation and storage activities.
105. At about the same time as he spoke to Paul, Gimelshtein also spoke to Fred Litwin, from whom Zola was considering purchasing CannTrust shares. Gimelshtein asked him why he was selling the shares and also inquired about the state of CannTrust's operations and whether there were any issues at CannTrust that gave Fred Litwin concerns.
106. Fred Litwin's answers were uniformly positive. He explained that he was selling the shares for the purposes of estate planning and portfolio management and not out of any concerns with the company. He touted the company's future prospects and stated that there was nothing that Zola should be concerned about. He omitted to state that CannTrust had begun the process of illegally cultivating marijuana and that CannTrust was illegally storing cannabis in the Vaughn Facility. He omitted the material risks that CannTrust's non-compliance with *Access to Cannabis for Medical Purposes Regulations* and planned non-compliance with the *Cannabis Act* posed to CannTrust's ability to

capitalize on the legalization of recreational cannabis. Fred Litwin knew or ought to have known about these facts. Among other things, Fred Litwin owned, controlled and was Chairman of Forum Financial, which had a management services agreement with CannTrust to assist it with its continuous disclosure and reporting requirements.

107. The Plaintiffs relied on these representations and omissions when making the decision to invest in CannTrust and suffered damage as a result.

Post-Purchase Misrepresentations

108. Following its investment in CannTrust, Zola and Gimelshtein continued to closely monitor and had numerous discussions with Aceto (CannTrust's CEO after his appointment in early October 2018) and Paul (Chairman after Aceto was appointed CEO in October 2018) about the state of CannTrust's operations.
109. On numerous occasions, including on October 29-30, 2018, December 7-8, 2018, December 17-18, 2018, December 21, 2018, January 8, 2019, January 18, 2019, January 21, 2019, March 21, 2019, March 29, 2019, June 12, 2019, June 17, 2019 and June 19, 2018, Gimelshtein, on behalf of himself and Zola, communicated with Aceto by way of in-person meetings, telephone calls, emails and text exchanges. These conversations related generally to CannTrust's business and operations and at no point did Aceto, who had always been aware of CannTrust's illegal cultivation operations, inform Gimelshtein that CannTrust had been illegally growing and selling cannabis and therefore that the company was exposed to the existential risk that CannTrust's Health Canada license would be suspended or revoked. At no point did Aceto inform Gimelshtein of CannTrust's other illegal activities, including the illegal storage of cannabis at the Vaughn Facility and the use of black-market cannabis seeds. To the contrary, he actively

misrepresented the company's operations and future prospects in order to keep Zola invested in CannTrust and obtain operational support and expertise from Gimelshtein.

110. On numerous occasions, including on December 7, 2018, February 27, 2019, March 1, 2019, March 29, 2019, May 20, 2019, June 9-11, 2019 and June 17, 2019, Gimelshtein, on behalf of himself and Zola, communicated with Paul by way of in-person meetings, telephone calls, emails and text exchanges. These conversations related generally to CannTrust's business and operations. Paul, who had always been aware of CannTrust's illegal cultivation operations, omitted to inform Gimelshtein that CannTrust had been illegally growing and selling cannabis and therefore that the company was exposed to the existential risk that CannTrust's Health Canada license would be suspended or cancelled for non-compliance. Paul likewise failed to inform Gimelshtein of CannTrust's other illegal activity, including its illegal storage of cannabis at the Vaughn Facility and use of black-market cannabis seeds. In all of their communications, Paul omitted to disclose the material risks that CannTrust's non-compliance with *Access to Cannabis for Medical Purposes Regulations* and ongoing non-compliance with the *Cannabis Act* posed to CannTrust's ability to capitalize on the legalization of recreational cannabis. To the contrary, he actively misrepresented CannTrust's future prospects and operations to ensure Zola's continued investment in the company.
111. For example, on March 29, 2019, Mr Gimelshtein stated in an email to Paul and Aceto that CannTrust's annual results "were incredibly disappointing and the share price reflects that." In his reply, which was copied to Aceto, Paul stated "... we did not cover the positives clearly [in our results]. The main issue for us was the delay in getting our Phase 2 ready which was a combination of equipment and construction issues. This is behind us and we expected [sic] annualized production of 50,000 kilos in 2019." Paul

further stated that CannTrust's "medical sales are very strong and continue to increase..." and also that their "rec[reation] sell through is excellent, again best value, quality and price. We need triple our current capacity and we are actioning our plans asap."

112. On May 9, 2019, Zola representative Rob McLay did a full-day tour of CannTrust's Niagara and Vaughan facilities, which was organised by CannTrust. McLay met with Paul for lunch. He asked Paul and other CannTrust employees extensive questions during the tour about CannTrust's operations, including its inventory levels and licensing status, and he asked further questions by email to Paul on May 15, 2019. During the tour and in reply to McLay's email, Paul and the other CannTrust employee omitted to inform McLay of the illegal cultivation that had taken place in the facility. They likewise failed to inform McLay of CannTrust's other illegal activity, including the illegal storage of cannabis at the Vaughn Facility and the use of black-market cannabis seeds. Paul also omitted to disclose the material risks that CannTrust's non-compliance with *Access to Cannabis for Medical Purposes Regulations* and ongoing non-compliance with the *Cannabis Act* posed to CannTrust's ability to capitalize on the legalization of recreational cannabis.
113. On June 19, 2019, Zola principal Ouass and Gimelshtein met with CannTrust's CEO at the time, the Defendant Aceto, at an event near San Francisco. They expressed concern about the delays CannTrust had experienced in obtaining cultivation expansion licenses, which they felt was depressing CannTrust's share price. They also asked whether CannTrust's low sales volumes were related to low inventory. Aceto stated that he understood the disappointment regarding the license but represented that the company remained on track to be granted the licenses. He also stated that the company had significant inventory levels and that the cause of the low sales volume was product

processing bottlenecks. Aceto failed to disclose that the company had cultivated cannabis illegally, stored cannabis illegally and cultivated black market cannabis seeds. Aceto further omitted to disclose the material risks that CannTrust's non-compliance with *Access to Cannabis for Medical Purposes Regulations* and ongoing non-compliance with the *Cannabis Act* posed to CannTrust's ability to capitalize on the legalization of recreational cannabis, in contravention of Health Canada laws.

THE TRUTH IS REVEALED AND SUBSEQUENT EVENTS

114. The truth was revealed by the First, Second and Third Corrective Disclosures.
115. On July 8, 2019, CannTrust issued the First Corrective Disclosure in a press release entitled "CannTrust Statement Regarding Health Canada Audit". It disclosed CannTrust's illegal cannabis cultivation, the sale of illegally cultivated cannabis, illegal sale and illegal storage compliance issues at the Vaughan Facility and that misleading information was provided to Health Canada. The First Corrective Disclosure stated that

CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) has received a compliance report from Health Canada notifying the Company that its greenhouse facility in Pelham, Ontario is non-compliant with certain regulations. CannTrust has accepted Health Canada's non-compliance finding and has taken actions to ensure current and future compliance.

The non-compliant rating is based on observations by the regulator regarding the growing of cannabis in five unlicensed rooms and inaccurate information provided to the regulator by CannTrust employees. Growing in unlicensed rooms took place from October 2018 to March 2019 during which time CannTrust had pending applications for these rooms with Health Canada. These rooms were constructed in accordance with regulations and Good Production Practices, and licenses were issued for each of the five rooms in April 2019. There are 12 rooms in total at the facility.

Health Canada has placed a hold on inventory which includes approximately 5,200kg of dried cannabis that was harvested in the previously unlicensed rooms in Pelham, until it deems that the Company is compliant with regulations. In addition, CannTrust has instituted a voluntary hold of approximately 7,500kg of dried cannabis equivalent at its Vaughan manufacturing facility that was produced in the previously unlicensed rooms.

CannTrust's operations at its Pelham and Vaughan facilities remain fully licensed and the Company continues to grow, cultivate, harvest and sell cannabis. Health Canada is conducting quality checks of product samples on hold at Pelham, with results expected in 10 to 12 business days. Due to the product on hold, some CannTrust customers and patients will experience temporary product shortages. The Company is exploring options to mitigate these shortages.

All product sold from the impacted rooms has passed quality control testing at Health Canada certified labs as well as CannTrust's own quality control processes and safety reviews.

"Our team has focused on building a culture of transparency, trust and excellence in every aspect of our business, including our interactions with the regulator. We have made many changes to make this right with Health Canada. We made errors in judgement, but the lessons we have learned here will serve us well moving forward," said Peter Aceto, Chief Executive Officer.

Corrective Actions and Additions to the CannTrust Executive Team

CannTrust has implemented a number of corrective actions including:

- Further comprehensive employee training
- Retained external advisors for an independent review of compliance processes
- Comprehensive review and update of processes and procedures
- Voluntarily advised Health Canada of issues that may impact compliance at its Vaughan facility regarding product storage

Improving the Quality and Compliance function at the Company has been a priority for senior leadership. The first executive addition under the new leadership team was Andrea Kirk, for the newly created role of Vice President, Quality. Ms. Kirk brings nearly 20 years of quality and compliance experience from the pharmaceutical industry to CannTrust and her mandate is to lead the Quality and Compliance Department. Since joining the Company in March 2019, she has hired and trained 17 quality and compliance professionals.

Financial Outlook

At this time, the impact of these matters on CannTrust's financial results are unknown until Health Canada completes its quality testing of product from Pelham which is currently on hold. Further updates will be provided as they become available.

116. Following the First Corrective Disclosure, CannTrust's share price declined materially on abnormally high trading volumes from C\$6.46 at the close of trading on July 5, 2019 to

C\$5.00 at the close of trading on July 8, 2019 and to C\$3.34 at the close of trading on July 12, 2018.

117. In an interview given to the *Financial Post* on July 8, 2019, Aceto confirmed that some of the illegally cultivated cannabis had been shipped to Canadian provinces for sale to cannabis consumers. Aceto also expressed his disappointment and surprise to the *Post* with respect to what had happened.
118. On July 9, 2019, Health Canada provided an emailed statement to the *Financial Post* stating that it had conducted a surprise inspection of CannTrust's Niagara Facility on June 17, July 3 and 4 and had seized 4,327 kg of implicated product. CannTrust was given until July 17th to respond to the non-compliance report.
119. Also on July 9, 2019, Paul gave an interview to the *Business News Network*. Paul said that "it was quite a shock" when he learned of the illegal cannabis being cultivated at the Niagara Facility and that if someone did so to meet increased demand that was "pretty flawed logic".
120. On July 10, 2019, *The Globe & Mail* published an article entitled "CannTrust allegedly used fake walls to hide pot from Health Canada". That article disclosed information provided by Nick Lalonde, a former employee of CannTrust from June 2017 to May 2019. Lalonde said that in November 2018, CannTrust employees (himself included) were asked to stay after hours to set up fake white poly walls in one of the unlicensed rooms. The fake poly walls were set up to hide several thousand cannabis plants in pictures to be taken of an unlicensed room in the Niagara Facility. The pictures were provided to Health Canada as part of routine licensing requirements. Lalonde emailed Health Canada on June 14 to blow the whistle on CannTrust's illegal behaviour. Health

Canada acted on the information and launched the surprise inspection of CannTrust on June 17, which eventually led to the non-compliance order. The article also noted that the Ontario Cannabis Store and the Alberta Gaming, Liquor and Cannabis Commission stopped selling impacted CannTrust cannabis products.

121. On July 11, 2019, CannTrust issued and filed a press release on SEDAR stating that it was halting the sale and shipment of all of its cannabis products while the Health Canada investigation was ongoing. CannTrust also announced the appointment of a special committee comprised of independent members of the board to investigate the matter.
122. On July 12, 2019, CannTrust filed two material change reports on SEDAR. One of the material change reports reiterated the contents of the First Corrective Disclosure. The other material change report related to CannTrust's hold on cannabis sales and shipments while the Health Canada investigation was ongoing.
123. On July 22, 2019, CannTrust issued and filed a press release on SEDAR entitled "CannTrust Special Committee Update". In that press release CannTrust stated that Marcovitch had been appointed as head of the special committee and that Page, Dawber and Kaden had been appointed as members. CannTrust further disclosed that the Committee had been struck to investigate the matters that resulted in non-compliance with Health Canada regulations. It stated that McCarthy Tétrault LLP had been appointed as legal counsel.
124. The Second Corrective Disclosure was released on July 23, 2019. *The Globe & Mail*, in an article entitled "CannTrust chairman, CEO were informed in November of unlicensed cannabis growing, emails show", reported that members of CannTrust's senior management and board, including both Aceto and Paul, had knowledge that cannabis was

being cultivated illegally in unlicensed rooms in the Phase 2 Expansion of the Niagara Facility. The article stated that:

Both the chairman and the chief executive officer of CannTrust Holdings Inc. were informed that the company was growing cannabis in unlicensed rooms about seven months before Health Canada uncovered the regulatory breach, internal e-mails show.

The company communications, seen by The Globe and Mail, show chairman Eric Paul and CEO Peter Aceto were made aware that cannabis was being cultivated in rooms at a growing facility in Southern Ontario that had yet to be licensed by the federal regulator, and that Mr. Paul counselled staff on how to respond.

In an e-mail dated Nov. 16, 2018, Graham Lee, CannTrust's director of quality and compliance, informed Mr. Aceto and other top executives about a Health Canada inspection that had just been completed. It had revealed several compliance breaches but missed the plants growing in unlicensed rooms.

"We dodged some bullets," Mr. Lee wrote. "[Health Canada] did not ask about RG8E/W, which are unlicensed rooms currently full of plants."

The e-mail outlines a number of "current risks," including plants growing in unlicensed rooms, the storage of cannabis in unlicensed rooms and the "large number of lost bottles [of cannabis] we have not reported."

"Although serious, on their own, each of these can be talked through with [Health Canada]. The concern is that together they will paint a picture with the regulator of a company not in control. We have dodged observations for items 1 and 6 despite having HC in the building," Mr. Lee wrote.

Along with Mr. Aceto, the e-mail was sent to Ian Abramowitz, a CannTrust executive who was chief financial officer at the time, and Ilana Platt, the company's vice-president of innovation and regulatory affairs.

The e-mail was forwarded to Mr. Paul later the same day, who responded, "We need to clearly point out that we have been diligent in submitting the applications for each new area and they have been slow in responding. We are supporting the legislation and we need their cooperation. Politely as always."

When asked about the e-mails, CannTrust responded with a statement from Robert Marcovitch, a CannTrust board member who is leading a special committee appointed to conduct an international investigation.

"The Independent Special Committee of the Board of Directors of CannTrust is in the final stages of a thorough investigation of these matters as part of our due diligence requirements. We expect to conclude this investigation within days and will take all appropriate actions immediately thereafter," Mr. Marcovitch said.

CannTrust is under investigation by Health Canada, after federal regulators found the Vaughan, Ont.-based cannabis producer grew 12,700 kilograms of cannabis in unlicensed rooms between October, 2018, and March of this year.

The value of CannTrust shares has fallen 47 per cent since July 8, when the company acknowledged that it had received a non-compliance order from Health Canada, raising concerns that CannTrust could lose its licence or be forced to destroy thousands of kilograms of cannabis worth tens of millions of dollars. CannTrust halted all sales on July 11, pending the outcome of the Health Canada investigation.

The special committee responded to Health Canada's queries on July 17, and is waiting to hear back from federal regulators. Health Canada has not indicated how it intends to respond to the regulatory breaches at CannTrust. It has the power to suspend and revoke cannabis licences, and to issue fines.

...

The scandal has cast the cannabis industry in an unfavourable light as it seeks to attract capital and expand operations in the United States, where federal legalization has yet to move forward. U.S. financial-services giants Bank of America, Citigroup and Jefferies LLC were among the underwriters of a US\$195.5-million CannTrust share offering in May to international investors, with the stock priced at US\$5.50 a share. Mr. Paul and members of the Litwin family, long-time backers of the company, sold US\$30-million of CannTrust stock as part of that offering.

...

The November e-mail was sent shortly after a targeted inspection of CannTrust's Pelham facility by Health Canada, which turned up several regulatory breaches, including poor paperwork, missing personnel and an incorrect protocol for releasing batches of cannabis, according to Mr. Lee's e-mail.

"The fallout from this inspection will be major observations, and possibly a 'critical' one. I am not ruling out a censure letter of some sort. That said, in the past I have had success explaining away these types of observations to HC, and they have dialed down the rhetoric. Practically, this may lead to increased inspections and more scrutiny, but hopefully will have no other immediate material affect," Mr. Lee wrote.

"That said, if that's all that happens, we got very lucky here. There are several points of exposure in our business we need to consider. I would not be surprised if HC visits Vaughan in the near future and that could compound HC's concerns," he added.

Mr. Lee outlined a number of risks, referring to room numbers in the facility: "1) RG8 is not licenced but has plants in it; 2) RG9 is not licenced but we are intending to put plants in it on Monday; 3) PA2A-E are not licenced but we have moved the encapsulation equipment into them and will begin running it next week."

Mr. Lee said CannTrust was storing product in unlicensed rooms at both its Pelham and Vaughan facilities.

“We have a large number of lost bottles we have not reported. I suspect due to bad counting rather than diversion [into the black market],” Mr. Lee added. “I will continue working to eliminate our exposure on all these items, but they remain a liability. Please advise of any actions you would like me to take.”

Health Canada appears to have begun its investigation into CannTrust’s unlicensed cultivation in mid-June, after receiving a whistle-blower tip from former CannTrust employee Nick Lalonde.

In an e-mail sent to Health Canada on June 14, Mr. Lalonde alleged that last fall he took part in efforts to stage photographs of an unlicensed room in the Pelham greenhouse by hanging temporary walls and moving plants. Health Canada can request photographs of facilities as part of the routine licensing process.

Federal inspectors had conducted three inspections on CannTrust’s Pelham greenhouse since the Cannabis Act came into effect in October, Health Canada spokesperson Tammy Jarbeau wrote in a statement to The Globe on July 12.

125. On July 24, 2019, a *Business News Network* article entitled “CannTrust CEO told staff ‘continue as planned’ on unlicensed pot” confirmed CannTrust’s senior management and, at least some, board members had knowledge of the illegal cannabis cultivation and directed it. The article stated:

Chief Executive Officer Peter Aceto told senior company officials to “continue as planned” and plant cannabis in an unlicensed room in mid-November, according to internal company documents obtained by BNN Bloomberg that establish a clear timeline of when illegal production was brought to management’s knowledge.

In minutes from weekly production meetings held by conference call from Nov. 14 to Nov. 28, seven CannTrust employees – including three vice-presidents as well as Graham Lee, the company’s director of quality and compliance – provided updates on developments at RG9, one of five unlicensed rooms at the company’s facility in Pelham, Ont. where Health Canada inspectors later determined the company grew thousands of kilograms of cannabis.

During a meeting held on Nov. 14, senior CannTrust staff stated that RG9 was not licensed by Health Canada and that further work in the room “needs up (sic) be run up the chain before anything is planted in there.” The room was estimated to be 50,000 square feet, roughly the same size as a football field, the minutes showed.

As well, Aceto – who was not present for any of the three production meetings – was to be informed by Lee that the RG9 room was not licensed, and that any repercussions if the company started planting in that room despite being unlicensed were “unknown.”

...

On Nov. 21, the minutes stated that RG9 remained unlicensed but Lee – who attended each of the production meetings – stated he spoke to Aceto about the unlicensed room and was instructed to “continue as planned.”

Minutes from the Nov. 28 production meeting stated CannTrust employees had submitted an application to Health Canada for the RG9 licence and were still waiting for approval from the federal regulator. “Still moving forward with planting today – 3 lots,” the minutes stated. One lot is approximately 1,000 cannabis plants, which can produce as much as 1,000 kilograms of marijuana.

126. On July 25, 2019, CannTrust filed a press release on SEDAR entitled “CannTrust announces Senior Leadership Changes”. In that press release CannTrust announced the termination of Aceto’s employment as CEO with cause. CannTrust appointed Marcovitch, former head of the special committee, as the new CEO. CannTrust also announced that it had asked for and received Paul’s resignation from his role as Chairman and as a board member. CannTrust further said it made a voluntary disclosure to Health Canada as a result of matters that were uncovered in the course of the investigation. CannTrust filed a material change report with respect to the contents of the July 25th press release on SEDAR on August 2, 2019.
127. On July 31, 2019, CannTrust announced the appointment of a financial advisor to assist in a review of strategic alternatives that included a sale, strategic investment, a business combination, and changes to CannTrust’s operations or strategy.
128. On August 1, 2019, CannTrust filed a press release on SEDAR entitled “CannTrust Announces Anticipated Late Filing of Financial Statements and Proposed Management Cease Trade Order”. In the press release CannTrust disclosed a possible restatement of previous financials as a consequence of Health Canada’s investigation and an investigation by the Joint Serious Offences Team of the Enforcement Branch of the OSC (a partnership between the OSC, the Royal Canadian Mounted Police and Ontario Provincial Police). The press release stated, in part:

Management is of the view that there is significant uncertainty with respect to the potential impact of pending Health Canada decisions on the valuation of the Company's inventory and biological assets and revenue recognition. As previously disclosed, the Company received a compliance report from Health Canada notifying it that its Niagara Facility in Pelham, Ontario is non-compliant with certain regulations based on observations made by Health Canada regarding the growing of cannabis in five unlicensed rooms from October 2018 to March 2019 and inaccurate information provided to Health Canada by employees. Health Canada placed a hold on inventory which includes approximately 5,200 kg of dried cannabis that was impacted by the previously unlicensed rooms at the Company's Niagara Facility. The Company instituted a voluntary hold of approximately 7,500 kg of dried cannabis equivalent at its extraction, manufacturing and packaging facility in Vaughan, Ontario that was impacted by the previously unlicensed rooms. The Company estimates the value of the impacted inventory and biological assets is approximately \$51 million as at June 30, 2019.

The uncertainty with respect to the nature, timing and potential financial impact of pending Health Canada decisions on the valuation of the Company's inventory and biological assets and revenue recognition relates to the fact that Health Canada has broad discretion to exercise a wide range of regulatory powers.

Until Health Canada has made determinations with respect to the exercise of its regulatory powers, the potential impact on the Company's operations and financial condition remains unknown. In addition to impacting the Company's financial disclosure in the Q2 Filings, the effects of the pending Health Canada decisions may also require restatement of certain of the Company's historical financial statements and related management's discussion and analysis for the periods ended December 31, 2018 and March 31, 2019 ("Restated Financials")

...

As announced yesterday, the Company's Special Committee of independent directors has commenced a review of strategic alternatives and retained Greenhill & Co. Canada Ltd. as its financial advisor. That review is in its early stages and is ongoing. Today, staff of the OSC advised the Special Committee's legal counsel that an investigation has been opened into matters and parties related to CannTrust and the investigation has been assigned to the Joint Serious Offences Team of the Enforcement Branch of the OSC.

On August 2, 2019, CannTrust filed a corresponding material change report on SEDAR.

129. On August 6, 2019, *The Globe & Mail* published an article entitled "Ex-CannTrust CEO Peter Aceto warned former chair Eric Paul of corporate governance problems". That article provided excerpts of a letter from Aceto to Paul dated December 31, 2018 which stated, in part, that "[m]anagement often receives conflicting instructions from board members. It is often unclear when and which board members need to be involved in

decision-making, and when decisions are made, they are often second-guessed” and that “[i]t is very difficult for management to confidently devise, adapt and execute strategy, build a confident high-performing team and to make the daily decisions that need to be made for the business to succeed.”

130. When asked about the letter, Aceto told *The Globe & Mail* that “[t]he bottom line is this: I knew what needed to be done to fix this company, but the lack of governance and proper executive decision-making authority was extremely concerning to me” and that “[w]hat I can tell you today was I felt very strongly that an almost complete lack of governance was at the root of this, which is why I brought it to the attention of the board in this formal manner.”

131. On August 9, 2019, CannTrust issued a press release on SEDAR entitled “CannTrust Announces the Withdrawal of Auditors’ Report”. That press release stated that:

the Company’s independent auditor, KPMG LLP, Chartered Professional Accountants (“KPMG”), has informed the Company that effective August 8, 2019, it is withdrawing its report dated March 27, 2019 on the Company’s consolidated financial statements as at and for the year ended December 31, 2018 and its interim report to the Audit Committee dated May 13, 2019 on the unaudited condensed interim consolidated financial statements as at and for the three month period ended March 31, 2019 (collectively, the “KPMG Reports”), and therefore, the KPMG Reports should no longer be relied upon. KPMG remains CannTrust’s independent auditor. The Company’s cooperation with KPMG is being directed by the Company’s Audit Committee and a special committee (the “Special Committee”) of its board of directors which is conducting an ongoing investigation into various matter.

As previously disclosed, Management is of the view that there is significant uncertainty with respect to the potential impact of pending Health Canada decisions on the valuation of the Company’s inventory and biological assets and revenue recognition. Accordingly, CannTrust cautions against any reliance on its consolidated financial statements as at December 31, 2018 and interim consolidated financial statements as at and for the three month period ended March 31, 2019. CannTrust is continuing to cooperate with Health Canada and the impact of the matters being investigated by the Special Committee on CannTrust’s financial results is unknown at this time. Further updates, to the extent material, will be provided as they become available.

KPMG's decision was prompted by the Company's caution against reliance on its financial statements for the year ended December 31, 2018 and for the three months ended March 31, 2019, as well as the recent sharing with KPMG of newly uncovered information from the Special Committee's investigation, including information that led to senior leadership changes announced on July 25, 2019. KPMG was not aware of the information recently shared by the Company when it issued the KPMG Reports and had relied upon representations made by individuals who are no longer at the Company.

132. On August 12, 2019, CannTrust issued a press release on SEDAR entitled "CannTrust Provides Interim Update". In that press release, CannTrust disclosed a further Health Canada finding of non-compliance this time at its Vaughan Facility. Specifically, as a result of its inspections between July 10-16, 2019 Health Canada made the following non-compliance findings:

- The conversion of five rooms from operational areas to storage areas, which were used for storage since June 2018 without prior approval of Health Canada;
- The construction of two new areas without prior approval of Health Canada, one of which was used to store cannabis since November 2018;
- Insufficient security controls at the manufacturing facility;
- Inadequate quality assurance investigations and controls;
- Standard operating procedures that did not to meet the requirements under regulations; and
- Documents or information that were not retained in a manner to enable Health Canada to complete its audit in a timely manner.

CannTrust said that it accepted the findings of non-compliance.

133. On September 6, 2019, the *Business News Network* published an article entitled "Black market pot entered CannTrust facility, flowed into legal market last year: Sources". That article disclosed that starting in 2018 senior operating staff at the Niagara Facility used black market cannabis seeds. CannTrust cultivated over 1000 cannabis plants using the black-market seeds. CannTrust mislabelled these seeds as being authorized cannabis strains and eventually sold that cannabis into the recreational market.

134. On September 17, 2019, CannTrust released the Third Corrective Disclosure. In a press release entitled “CannTrust Discloses Notice of License Suspension”, CannTrust stated:

VAUGHAN, ON, Sept. 17, 2019 /CNW/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX: TRST, NYSE: CTST) announced that it received late this morning a Notice of Licence Suspension (the “Notice”) under section 64(1) of the Cannabis Act (Canada). The Notice cites the Company’s previous non-compliance with certain requirements of the Cannabis Act (Canada) and the regulation made thereunder (the “Cannabis regulations”) in respect of the matters that the Company has been discussing with Health Canada.

The Notice states that Health Canada has suspended CannTrust’s authority to produce cannabis, other than cultivating and harvesting, and to sell cannabis. As such, the Notice constitutes a partial suspension of the Company’s licence for standard cultivation and a full suspension of its licences for standard processing, medical sales, cannabis drugs and research issued under the Cannabis regulations. While the suspension remains in effect, CannTrust will be permitted to cultivate and harvest existing lots or batches previously propagated, as well as conducting ancillary activities to those lots, including drying, trimming and milling. During the suspension, CannTrust may not propagate new lots or batches of cannabis or engage in the sale or distribution of cannabis.

The Notice states that Health Canada will reinstate CannTrust’s licences under section 64(4) of the Cannabis Act if the reasons for the suspension no longer exist or if CannTrust demonstrates that the suspension was unfounded. The Notice also states that Health Canada considers that implementation of the following measures could potentially address the public health and safety risks that contributed to Health Canada’s decision to issue the Notice:

Measures to ensure that cannabis will be produced and distributed only as authorized, including measures to control the movement of cannabis in and out of CannTrust’s site;

Measures to recover cannabis that was not authorized by CannTrust’s licence;

Measures to improve key personnel’s knowledge of, and compliance with the provisions of the Act and the Regulations that apply to CannTrust; and,

Measures for improving the manner in which records are kept, including a plan to improve the inventory tracking, and any interim measures to ensure that information provided to Health Canada can be reconciled.

The Company’s management and Board of Directors are reviewing the Notice with the Company’s counsel and other advisors.

Over the past two months, the Company has moved swiftly to assess and address Health Canada’s concerns, including areas of operational non-compliance. The Company remains committed to being in full regulatory compliance.

135. Following the Third Corrective Disclosure, CannTrust's shares declined materially on abnormally high trading levels from C\$1.99 per share at the close of trading on September 16, 2019 to \$1.70 per share at the close trading on September 17, 2019.
136. On October 14, 2019, CannTrust issued a press release entitled "CannTrust Advances its Plan Towards Regulatory Compliance". In that press release, CannTrust announced, among other things, that it was destroying \$12 million in biological assets and \$65 million worth of inventory that was not authorized by its license as part of its plan to return to regulatory compliance.
137. On October 24, 2019, CannTrust issued a press release entitled "CannTrust Provides Progress Update Regarding Remediation Plan." In that press release Dawber, chair of the Special Committee, made the self-serving statement that the Special Committee found no evidence that any of the remaining members of the board "were aware of or engaged in any non-compliance issue." The members of the Special Committee—Dawber, Kaden, Page and Marcovitch (prior to his appointment as CEO)—were all members of CannTrust's board while illegal activity was occurring and remained members of the board at the time of Dawber's statement. The press release gave no indication of what steps, if any, were taken to address the obvious conflict of interest the members of the Special Committee had in investigating their own complicity in the illegal conduct and the complicity of the other remaining directors who were similarly situated.
138. In its October 24, 2019 press release CannTrust also confirmed that it will be restating and refiling its financial statements for the 2018 year and the first quarter of 2019. The company indicated that it plans to do so "within the next 60 days."
139. John Kaden's resignation from CannTrust's board was announced on October 28, 2019.

140. The Plaintiffs were not aware of the facts contained in the corrective disclosures prior to their release.

POST-CORRECTION INDIVIDUAL MISREPRESENTATIONS MADE TO THE PLAINTIFFS

141. On the day of the First Correction, July 8, 2019, Zola principle Ouass and Gimelshtein spoke to then-Chairman Paul by telephone. Gimelshtein and Ouass were in the process of deciding whether to maintain their investment in CannTrust, given the revelations of CannTrust's illegal cannabis production. Ouass and Gimelshtein advised Paul of this.
142. Paul misled them. He told them that he was not aware of the illegal cannabis growing until the news on July 8, 2019 broke, something that has been proven to be untrue. Paul stated that he "had been dealt this hand" and was in the process of addressing the purported issue, which he suggested was not systemic but rather the actions of a single or small group of individuals. In fact, Paul assured Ouass and Gimelshtein that the issue did not extend into the highest levels of CannTrust's management team. He maintained that the company was well-positioned for future growth.
143. Paul failed to tell Ouass and Gimelshtein that CannTrust had cultivated cannabis illegally, stored cannabis illegally and cultivated black market cannabis seeds under his guidance. Paul omitted the material risks that CannTrust's non-compliance with *Access to Cannabis for Medical Purposes Regulations* and ongoing non-compliance with the *Cannabis Act* posed to CannTrust's ability to capitalize on the legalization of recreational cannabis, in contravention of Health Canada laws.
144. Zola and Gimelshtein relied on these representations when making the decision to maintain their investment in CannTrust and suffered damage as a result. Since that time,

the company's shares have declined further, from a closing price of \$5.00 CAD on July 8th to their current trading price of approximately \$1.30 (as of mid-November, 2019).

145. Following the First Correction on July 8, 2019, Gimelshtein communicated, via telephone calls and text messages, with Kaden. In a text message to Gimelshtein, Kaden described Aceto's post-correction communications to the media as "INSANE!!" and indicated that CannTrust's investor relations firm had been considering resigning, largely because they were uncomfortable with Aceto and Paul continuing to be in charge. Moreover, during phone conversations Kaden told Gimelshtein that it was crazy that CannTrust's illegal conduct was not disclosed earlier and that Kaden had failed to fulfill his legal obligations as director of CannTrust.

RIGHTS OF ACTION

Part XXIII.1 of the *OSA*: Secondary Market Misrepresentations

146. The Plaintiffs assert the cause of action under Part XXIII.1 of the *OSA* against CannTrust, and the Individual Defendants for the Impugned Documents and for the failure to disclose a material change in a timely manner. The Plaintiffs assert the same cause of action against Abramowitz and Paul for misrepresentations in the CEO and CFO certifications of CannTrust's periodic filings they provided.
147. The Impugned Documents and CEO and CFO certifications contained the misrepresentations alleged herein.
148. Each of the Core Documents is a "core document" within the meaning of the *OSA*. Each of the Non-Core Documents and CEO and CFO certifications are "documents" within the meaning of the *OSA*.

149. CannTrust is a reporting issuer within the meaning of the *OSA*. CannTrust is responsible for the misrepresentations and for the failure to make timely disclosure of the material change particularized herein.
150. Each of the Individual Defendants who was a director of CannTrust at the time that CannTrust released one or more of the Impugned Documents is liable for the misrepresentations alleged to be contained in such document or documents by virtue of having been a director at the time of their release.
151. Each of the Individual Defendants who was an officer of CannTrust permitted, authorized or acquiesced to the release of all Impugned Documents during their tenure as an officer of CannTrust and is therefore liable for the alleged misrepresentations contained therein.
152. With respect to the Non-Core Documents, CannTrust and the Individual Defendants knew that they contained the alleged misrepresentations or, in the alternative, deliberately avoided acquiring such knowledge or, in the further alternative, were guilty of gross misconduct in connection with the release of the document. They are liable for the alleged misrepresentations contained therein.
153. With respect to the CEO and CFO certifications, each of Paul and Abramowitz, permitted, authorized or acquiesced in the release of the certifications, and knew that the certifications contained the alleged misrepresentations or, in the alternative, deliberately avoided acquiring such knowledge or, in the further alternative, were guilty of gross misconduct in connection with the release of the certifications. They are liable for the alleged misrepresentations contained therein.
154. Each of the Individual Defendants authorized, permitted or acquiesced in the failure to make timely disclosure of the material changes particularized herein.

155. For each alleged undisclosed material change, CannTrust and the Individual Defendants:
- (a) knew, at the time that the failure to make timely disclosure first occurred, of the change and that it was a material change; or (b) at the time or before the failure to make timely disclosure first occurred, deliberately avoided acquiring knowledge of the change or that the change was a material change; or (c) are guilty of gross misconduct in connection with the failure to make timely disclosure. CannTrust and the Individual Defendants are liable under the *OSA* for the failure to disclose the material change.
156. Each of the Individual Defendants authorized, permitted or acquiesced in the making of the misrepresentations particularized herein and the failure to make timely disclosure of the material changes alleged herein while knowing them to be misrepresentations or failures to make timely disclosure. Each Individual Defendant is, therefore, liable for the entirety of the damages claimed herein.

Negligent Misrepresentation

157. The Plaintiffs plead negligent misrepresentation against CannTrust and the Individual Defendants for the Impugned Documents and the specific pre-investment representations and post-correction representation (detailed at paragraphs 79-96, 101-107 and 140-143) made to Gimelshtein, who was also serving as Zola's agent, by the Defendants Fred Litwin and Paul.
158. Paul and Fred Litwin made the specific misrepresentations to solicit or maintain the Plaintiffs' investment in CannTrust and the Plaintiffs relied upon these misrepresentations when deciding to invest, or to continue to invest in the case of the post-correction representation.

159. The Impugned Documents were prepared and disseminated to provide material information and induce the Plaintiffs to acquire and hold their CannTrust shares.
160. CannTrust and the Individual Defendants undertook, at all material times, to prepare and disseminate the Impugned Documents with reasonable care for the aforementioned purpose. The Defendants intended and were aware that the Plaintiffs would rely reasonably upon the Impugned Documents to their detriment in deciding to purchase CannTrust shares.
161. CannTrust and the Individual Defendants further knew and intended that the information contained in the Impugned Documents would be incorporated into the price of CannTrust's publicly traded shares such that the trading price of those shares would at all times reflect the information contained in the Impugned Documents.
162. CannTrust and the Individual Defendants were responsible for the preparation of the Impugned Documents and undertook to do so for the benefit of, and to be relied upon by, the Plaintiffs.
163. CannTrust and the Individual Defendants, therefore, had a duty of care at common law, informed by the obligations referred to at paragraphs 51 to 65 above, to exercise due care and diligence to ensure that the Impugned Documents fairly and accurately disclosed all material information about CannTrust's business, including the compliance of its cannabis cultivation, processing, storage and sales practices with the regulatory regime.
164. CannTrust and the Individual Defendants breached that duty by failing to take reasonable or any steps to ensure that the Impugned Documents did not contain the alleged misrepresentations particularized herein.

165. CannTrust and the Individual Defendants had exclusive access to information about CannTrust's business and operations. As such, they were the primary source of information with respect to CannTrust's cannabis cultivation, processing, storage and sales practices and CannTrust's compliance with legal obligations related thereto.
166. The Plaintiffs directly or indirectly relied upon the alleged misrepresentations in deciding to purchase CannTrust's shares and suffered damage when the alleged misrepresentations were publicly corrected by the First, Second and Third Corrective Disclosures.
167. The Plaintiffs suffered damages as a consequence of their reliance on the Impugned Documents.
168. The Plaintiffs suffered damages as a consequence of their reliance on Fred Litwin and Paul's pre-investment individual misrepresentations and Paul's post-correction individual misrepresentations.

Relief from Oppression

169. As against CannTrust and the Individual Defendants who are directors of CannTrust, the Plaintiffs seek relief from oppression pursuant to section 248 of the *OBCA*.
170. CannTrust is incorporated pursuant to the *OBCA*.
171. The Plaintiffs had reasonable expectations about the way the business and affairs of CannTrust would be conducted.
172. The Plaintiffs' reasonable and legitimate expectations were that:
- (a) CannTrust would conduct its business and affairs in accordance with the legislation and regulation governing licensed cannabis producers, namely the

Cannabis Act and its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*;

- (b) CannTrust and its directors and officers would abide by continuous disclosure and other reporting obligations prescribed by the *OSA* and applicable securities regulatory instruments; and
- (c) CannTrust's directors and officers would act honestly and in good faith with a view to CannTrust's best interests, and exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances.

173. CannTrust and its officers and directors breached those reasonable expectations by:

- (a) knowingly operating in violation of the *Cannabis Act* and its predecessor regulation the *Access to Cannabis for Medical Purposes Regulations*, as alleged herein; and
- (b) breaching the *OSA* and securities regulations by making the misrepresentations in the Impugned Documents (paragraphs 79 to 97), by making the pre-investment individual misrepresentations (paragraphs 101 to 107), by making the post-investment individual misrepresentations (paragraphs 108 to 113) and by making the post-correction misrepresentations (paragraphs 140-143).

174. The violation of the Plaintiffs' reasonable expectations was oppressive, unfairly prejudicial to and unfairly disregarded the Plaintiffs' interests.

175. As a result, the Plaintiffs seek relief pursuant to section 248 of the *OBCA*, including compensation for their damages and the losses they have suffered.

Insider Trading

176. As against Fred Litwin, the Plaintiffs claim damages for insider trading pursuant to section 134 of the *OSA*.
177. Forum Financial is a person or company that was engaging in business or professional activity with or on behalf of CannTrust. Fred Litwin was a director, officer or employee of Forum Financial. Fred Litwin was, therefore, in a special relationship with CannTrust.
178. Alternatively, Fred Litwin learned of material facts and material changes with respect to CannTrust from CannTrust insiders (including but not limited to Mark Litwin, Paul, Mark Dawber and Abramowitz) when he knew or ought to have reasonably known that those individuals were CannTrust insiders. Fred Litwin was, therefore, in a special relationship with CannTrust.
179. In breach of sections 76 and 134 of the *OSA*, Fred Litwin sold CannTrust shares to the Plaintiffs with knowledge of the undisclosed material facts and/or material changes particularized herein.
180. As a result of the conduct in breach of section 76 and 134 of the *OSA*, the Plaintiffs have suffered damages.

DAMAGES AND COMPENSATION FOR OPPRESSION

181. The Plaintiffs would not have acquired any CannTrust shares but for the Defendants' negligent misrepresentations. As a consequence, the Plaintiffs suffered damages in the following amounts:
- (a) the full amount of the purchase price paid for its CannTrust shares;
 - (b) the transaction costs for its CannTrust share purchases; and

- (c) the lost returns from alternative investments the Plaintiffs would have made had they not invested in CannTrust.
182. Alternatively, the Plaintiffs would have acquired the CannTrust shares at a materially lower price but for the Defendants' misrepresentations and failure to disclose material changes in CannTrust's business, operations and capital.
183. The price of CannTrust's securities on the secondary market and those acquired by the Plaintiffs from Fred Litwin was directly affected by the alleged misrepresentations and the failure to disclose the material changes. The Defendants were aware at all material times of the effect of CannTrust's disclosure documents and disclosure of material changes upon the price of its shares. Had the Defendants not made the alleged misrepresentations and, instead, disclosed the truth, then CannTrust's shares' market price would have incorporated that information and declined by a material amount.
184. As a consequence, the Plaintiffs suffered damages in the following amounts:
- (a) the difference between the purchase price the Plaintiffs paid for their CannTrust shares and the price the Plaintiffs would have paid had the alleged misrepresentations and omissions not been made; and
- (b) the lost returns from alternative investments the Plaintiffs would have made with the money they saved due to the lower acquisition price.
185. Further or in the alternative, the Plaintiffs are entitled to the statutory damages for secondary market misrepresentations prescribed by Part XXIII.1 of the *OSA* for their CannTrust share acquisitions.

186. Further or in the alternative, had CannTrust and the Individual Defendants not engaged in the illegal and oppressive conduct particularized herein, then there would have been no threat to CannTrust's status as a licensed producer, CannTrust would not have had its licensed suspended and CannTrust would not have suffered any of the other adverse material impacts that have resulted from its illegal conduct. Consequently, the Plaintiffs seek compensation for the loss they have suffered in the amount of the difference between the market value of CannTrust's shares and the market value of those shares had CannTrust not engaged in the illegal conduct particularized herein.

RESCISSION

187. The Plaintiffs purchased CannTrust shares directly from Fred Litwin. Paul's and Fred Litwin's alleged misrepresentations and omissions to the Plaintiffs were fraudulent or contained an error in *substantialibus*. The Plaintiffs would not have acquired CannTrust shares from Fred Litwin had these material misrepresentations and omissions not been made. The misleading statements and omissions were intended to and did induce the Plaintiffs to purchase the CannTrust shares from Litwin. The Plaintiffs are, therefore, entitled to rescind their CannTrust share transaction with Litwin.

188. The Defendants' misrepresentations and omissions to the Plaintiffs were fraudulent or contained an error in *substantialibus*. The Plaintiffs would not have acquired CannTrust shares on the secondary market had these material misrepresentations and omissions not been made. The misleading statements and omissions induced the Plaintiffs to purchase the CannTrust shares on the secondary market. The Plaintiffs are, therefore, entitled to rescind their CannTrust share purchases on the secondary market.

EXEMPLARY AND PUNITIVE DAMAGES

189. CannTrust and the Individual Defendants made deliberate decisions to act illegally and, in fact, carried out that illegal conduct for an extended time period. CannTrust and the Individual Defendants then made a deliberate decision not to disclose this information to the Plaintiffs specifically and the market generally. This was despite the Plaintiffs' repeated and ongoing inquiries to some or all of the Defendants as to the status of CannTrust's cannabis related business. The Defendants' conduct was high-handed, reckless, without care, deliberate and in wanton disregard of the Plaintiffs' rights and interests. The Defendants' conduct purposely artificially inflated the price of CannTrust's shares and caused a large loss to the Plaintiffs and other CannTrust shareholders. Such harm to investors and Canada's capital markets generally requires a deterrent award.
190. To achieve its deterrence and public interest objectives, any punitive damages award should be significant. The punitive damages award must be substantial to reflect both the underlying illegal conduct and the Defendants' deliberate decision not to disclose that information to the market. A punitive damages award must be sufficiently large to ensure that directors, officers, issuers and other responsible parties cannot easily treat liability for making misleading public and private statements to investors as a mere cost of doing business and a license to breach the law.

VICARIOUS LIABILITY

191. CannTrust is vicariously liable for the acts and omissions of the Individual Defendants particularized herein.
192. CannTrust's acts and omissions particularized and alleged herein were authorized, ordered and done by the Individual Defendants and other agents, employees and

representatives of CannTrust, while engaged in the management, direction, control and transaction of the business and affairs of CannTrust.

193. By virtue of the relationship between CannTrust and Individual Defendants, such acts and omissions are, therefore, not only the acts and omissions of the Individual Defendants, but also are the acts and omissions of CannTrust.
194. At all material times, the Individual Defendants were directors and/or officers of CannTrust. As their acts and omissions are independently tortious, they are personally liable for same to the Plaintiffs.

REAL AND SUBSTANTIAL CONNECTION WITH ONTARIO

195. The Plaintiffs plead that this action has a real and substantial connection with Ontario because, among other things:
- (a) CannTrust is headquartered in Ontario;
 - (b) CannTrust is a reporting issuer on the TSX;
 - (c) the Plaintiffs acquired CannTrust shares in Ontario and suffered damages and losses in Ontario; and
 - (d) CannTrust conducts extensive business in Ontario, including the cultivating, processing, storage, marketing and sale of cannabis.

SERVICE OUTSIDE OF ONTARIO

196. The Plaintiffs may serve the Statement of Claim outside of Ontario without leave in accordance with rule 17.02 of the *Rules of Civil Procedure*, because this claim is:
- (a) a claim in respect of personal property in Ontario (rule 17.02(a));

- (b) a claim in respect of a tort committed in Ontario (rule 17.02(g)); and
- (c) a claim against a person or entity carrying on business in Ontario (rule 17.02(p)).

RELEVANT LEGISLATION AND PLACE OF TRIAL

197. The Plaintiffs plead and rely on the *CJA*, the *CPA*, the *OSA* and securities regulatory instruments, and the *OBCA*.

198. The Plaintiffs propose that this action be tried in the City of Toronto, in the Province of Ontario.

November 27, 2019

Siskinds LLP

680 Waterloo Street
P.O. Box 2520
London, ON N6A 3V8

Michael G. Robb (LSO# 45787G)
Garett M. Hunter (LSO# 71800D)
Tel: 519-660-2121
Fax: 519-672-6065

100 Lombard Street
Suite 302
Toronto, ON M5C 1M3

Alex Dimson (LSO#: 56129U)
Tel: 416-594-4394
Fax: 416-362-2610

Wright Henry LLP

200 Wellington St. West
Suite 602
Toronto, ON M5V 3C7

Michael Wright
Danielle Stampley
Tel: 416-306-8280
Fax: 416-306-8281

Lawyers for the Plaintiff

Zola Finance Holdings Ltd. *et al* CannTrust Holdings Inc. *et al*
Plaintiffs and Defendants

Court File No.:

**ONTARIO
SUPERIOR COURT OF JUSTICE**

Proceeding commenced at Toronto

STATEMENT OF CLAIM

Siskinds LLP
680 Waterloo Street
P.O. Box 2520
London, ON N6A 3V8

Michael G. Robb (LSO#: 45787G)
Garrett M. Hunter (LSO #: 71800D)
Tel: 519-660-2121
Fax: 519-672-6065

Barristers & Solicitors
100 Lombard Street
Suite 302
Toronto, ON M5C 1M3

Alex Dimson (LSO#: 56129U)
Tel: 416-594-4394
Fax: 416-362-2610
Lawyers for the Plaintiff

Wright Henry LLP
200 Wellington St. West
Suite 602
Toronto, ON M5V 3C7

Michael Wright
Danielle Stampley
Tel: 416-306-8280
Fax: 416-306-8281

This is Exhibit "B" mentioned and referred to in the Affidavit of Igor Gimelshtein, sworn before me over video teleconference this 26th day of October, 2020, with both the affiant and the commissioner, Alex Dimson, being located in the City of Toronto, in the Province of Ontario.

DocuSigned by:

Alex Dimson

6DBE7D0F8A024D6...

A Commissioner, etc

Share Prices

	05-Jul-19	05-Sep-19	05-Nov-19	06-Jan-20	05-Mar-20	05-May-20	06-Jul-20	04-Sep-20	23-Oct-20	% Decline
CannTrust Holdings Inc.	C\$6.46	C\$2.32	C\$1.56	C\$1.53	C\$0.85	-	-	-	-	-86.8%
Canopy Growth Corp.	C\$52.63	C\$34.94	C\$26.17	C\$26.02	C\$22.45	C\$22.17	C\$22.95	C\$21.11	C\$25.94	-50.7%
Aurora Cannabis Inc.	C\$118.32	C\$93.00	C\$59.16	C\$29.52	C\$21.24	C\$11.88	C\$16.44	C\$11.12	C\$6.13	-94.8%
Cronos Group Inc.	C\$20.00	C\$15.34	C\$10.87	C\$8.82	C\$7.95	C\$8.11	C\$8.71	C\$7.02	C\$7.64	-61.8%
OrganiGram Holdings Inc.	C\$8.57	C\$6.30	C\$4.57	C\$2.80	C\$2.79	C\$2.10	C\$2.10	C\$1.49	C\$1.65	-80.7%
Aphria Inc.	C\$8.94	C\$9.07	C\$6.76	C\$6.20	C\$4.52	C\$5.08	C\$5.97	C\$5.98	C\$5.97	-33.2%
Tilray Inc.	C\$46.98	C\$32.08	C\$22.43	C\$15.5	C\$11.2	C\$7.39	C\$7.85	C\$5.92	\$6.73	-85.67%
Hexo Corp.	C\$6.81	C\$5.99	C\$2.70	C\$1.90	C\$1.61	C\$0.72	C\$0.97	C\$0.87	C\$1.00	-85.3%

IN THE MATTER OF THE COMPANIES' CREDITORS ARRANGEMENT
 ACT, R.S.C. 1985, c. C-36, AS AMENDED AND IN THE MATTER OF A
 PLAN OF COMPROMISE OR ARRANGEMENT OF CANNTTRUST
 HOLDINGS INC. ET AL.

Court File No.: CV-20-00638930-00CL

ONTARIO

**SUPERIOR COURT OF JUSTICE
 (COMMERCIAL LIST)**

Proceeding commenced at Toronto

**AFFIDAVIT OF IGOR GIMELSHTEIN
 (Sworn October 26, 2020)**

Siskinds LLP

680 Waterloo Street

P.O. Box 2520

London, ON N6A 3V8

Michael G. Robb (LSO#: 45787G)

Garett M. Hunter (LSO #: 71800D)

Tel: 519-660-2121

Fax: 519-672-6065

Barristers & Solicitors

100 Lombard Street

Suite 302

Toronto, ON M5C 1M3

Alex Dimson (LSO#: 56129U)

Tel: 416-594-4394

Fax: 416-362-2610

Lawyers for the Plaintiff

Wright Henry LLP

200 Wellington St. West

Suite 602

Toronto, ON M5V 3C7

Michael Wright

Danielle Stampley

Tel: 416-306-8280

Fax: 416-306-8281

Court File No. CV-20-00638930-00CL

ONTARIO
SUPERIOR COURT OF JUSTICE
(COMMERCIAL LIST)

CM/sp

IN THE MATTER OF THE *COMPANIES' CREDITORS ARRANGEMENT ACT*,
R.S.C. 1985, c. C-36, AS AMENDED

AND IN THE MATTER OF A PLAN OF COMPROMISE OR ARRANGEMENT
OF CANNTRUST HOLDINGS INC., CANNTRUST INC.,
CTI HOLDINGS (OSOYOOS) INC. AND ELMCLIFFE INVESTMENTS INC.

Applicants

This is the Cross-Examination of SERGE KALLOGHLIAN
on his Affidavit sworn the 20th day of January, 2021, held
via videoconference at the Offices of VICTORY VERBATIM
REPORTING SERVICES, Suite 900, 222 Bay Street, Toronto-
Dominion Centre, Toronto, Ontario, on the 27th day of
January, 2021.

A P P E A R A N C E S:

MICHAEL WRIGHT }	---	for Zola Finance
DANIELLE STAMPLEY}		Holdings Ltd.
ALEX DIMSON }		
DAVID R. WINGFIELD	---	for Serge Kalloghlian
SHANE D'SOUZA }	---	for CannTrust Holdings
JAMEY GAGE }		Inc. and CannTrust
TREVOR COURTIS}		Inc.

S. Kalloghlian - 2

INDEX OF PROCEEDINGSPAGE NUMBER

SERGE KALLOGHLIAN, affirmed

Cross-Examination by:
Mr. Wright

3 - 41

INDEX OF REFUSALS

42

CERTIFICATION

43

S. Kalloghlian - 3

1 --- upon convening at 4:00 p.m.

2 --- upon commencing at 4:02 p.m.

3
4 SERGE KALLOGHLIAN, affirmed

5 CROSS-EXAMINATION BY MR. WRIGHT:

6
7 1. Q. Mr. Kalloghlian, you swore an
8 affidavit on January 20, 2021, and it is found at
9 page 211 of the CannTrust motion record. Do you
10 have that before you?

11 A. Yes.

12 2. Q. And paragraph 3 of that affidavit
13 states that it was sworn in support of CannTrust's
14 motion for an order appointing representatives and
15 representative counsel, correct?

16 A. Yes, that's what it says.

17 3. Q. And as I understand it, your firm,
18 along with three other firms in Canada, have created
19 a coalition to represent proposed class members?

20 A. Yes.

21 4. Q. And there are two plaintiffs in the
22 action, as I understand it, Patrick Hurusa and
23 Dharambir Singh. Is that correct?

24 A. Those are two of the proposed
25 representatives.

S. Kalloghlian - 4

1 5. Q. And at this point, they are the only
2 two proposed representatives, correct?

3 A. No, there are also proposed
4 representatives of U.S. securities claimants, and
5 those are the plaintiffs in the U.S. class action
6 commenced by Labaton.

7 6. Q. Right. I'm just...sorry, just to be
8 clear, I'm only asking about the Canadian or the
9 Ontario class action that has led to the
10 coalition...oh, sorry, I understand there may be two
11 coalitions. There are four firms acting in the
12 Ontario class action, correct?

13 A. That's correct.

14 7. Q. And there are two plaintiffs that
15 they represent, correct?

16 A. Yes.

17 8. Q. Okay. As I understand it from the
18 affidavit of Mr. Hurusa that you appended to your
19 affidavit, he estimates his losses on CannTrust
20 shares as approximately \$150,000. Is that correct?

21 A. I don't recall. I'm going to that
22 now.

23 9. Q. Okay. It's page 584 of the motion
24 record.

25 A. It says:

S. Kalloghlian - 5

1 "...I suffered losses of approximately
2 150,000 on my investments..."

3 10. Q. Okay. Then Mr. Singh's affidavit,
4 which is also appended to your affidavit, states
5 that he and his wife lost approximately \$250,000.
6 Is that correct?

7 A. Paragraph 4 of his affidavit says:
8 "...My business, my wife and I collectively
9 suffered losses in excess of 250,000 on our
10 investments..."

11 11. Q. And it's correct that no motion for
12 certification has been granted in Ontario with
13 respect to the proposed class proceeding, correct?

14 A. Correct.

15 12. Q. And also no motion for certification
16 has been granted in the United States for that
17 proposed class proceeding, correct?

18 A. I'm not aware of any.

19 13. Q. So your law firm and the three law
20 firms you're working with represent three investors,
21 Mr. Hurusa, Mr. Singh and his spouse, whose losses
22 are estimated to be approximately \$400,000, correct?

23 A. We represent Mr. Singh and Mr.
24 Hurusa...sorry, yes, Mr. Singh and Mr. Hurusa. So
25 sorry, can you repeat the question?

S. Kalloghlian - 6

1 14. Q. Sure. Currently your law firm and
2 the three law firms you are working with in Ontario
3 represent three investors whose losses are estimated
4 to be approximately \$400,000. Is that correct?

5 A. Well, we represent two investors,
6 but yes, I don't take issue with the number that you
7 have said. The losses are approximately \$400,000.

8 15. Q. Okay, fair enough. Mr. Singh, from
9 the material I have reviewed, says that he and his
10 wife lost approximately \$250,000, but I don't know
11 how much he lost and how much his wife lost. Do you
12 have that information?

13 A. Not off the top of my head, no.

14 16. Q. So maybe the best way to put it is
15 you and the three law firms represent two investors
16 whose estimated losses are a maximum of \$400,000.
17 Is that fair?

18 A. I don't mean to nitpick. I just
19 want to make sure the answer is accurate. I don't
20 know if it's a maximum. These say approximately
21 250,000. So it may be a maximum of 400. It might
22 be a little bit more.

23 17. Q. Okay.

24 A. It's around that.

25 18. Q. Okay. I take it through the

S. Kalloghlian - 7

1 mediation that has been occurring as part of the
2 CCAA process, you have not had instructions or a
3 court order authorizing you to act for any party
4 other than those two investors who have estimated
5 losses of approximately \$400,000, correct?

6 MR. WINGFIELD: Not entirely correct.
7 There is, as you know, a carriage motion
8 that prohibits any other law firm from
9 acting in the putative class proceedings,
10 which have been stayed by CannTrust's CCAA
11 proceedings.

12 19. MR. WRIGHT: Right. I don't see how
13 that makes my question incorrect, but I
14 don't really want to debate it.

15 20. MR. WRIGHT: Do you have instructions or
16 do you act for any party other than those
17 two investors whose losses are
18 approximately \$400,000?

19 MR. WINGFIELD: We take instructions
20 from those two people...

21 21. MR. WRIGHT: Right.

22 MR. WINGFIELD: ...is a more accurate
23 way of describing things.

24 22. MR. WRIGHT: Right, and you don't have a
25 court authorization to act for any other

S. Kalloghlian - 8

1 parties, other than those two investors at
2 the present time, correct?

3 MR. WINGFIELD: Correct.

4 23. MR. WRIGHT: And I had a couple of
5 questions about the restructuring support
6 agreement, which is an exhibit to Mr.
7 Guyatt's affidavit, and particularly if you
8 can just turn with me...

9 MR. D'SOUZA: Mr. Wright, sorry, I just
10 wanted to say based on my understanding of
11 the Zola plaintiff's position, the only
12 contested issue on Jan. 29th is whether the
13 proposed representatives should be
14 appointed to protect the interests of the
15 unrepresented securities claimants, which
16 is a fairly narrow issue. So I'll allow
17 some leeway. I just want to give you a
18 heads up, but not a lot.

19 24. MR. WRIGHT: Okay, well, I'm not sure
20 what prompted that, but I'll just carry on.

21 MR. D'SOUZA: Well, you're going to the
22 restructuring support agreement, which is
23 not before this court for approval on
24 Friday, and has nothing to do with the
25 appointment of the proposed

S. Kalloghlian - 9

1 representatives. So I just wanted to give
2 you...

3 25. MR. WRIGHT: I think that's quite
4 debatable, but...as to whether it has
5 nothing to do with it.

6
7 BY MR. WRIGHT:

8 26. Q. But as I understand it, in the
9 restructuring support agreement there are certain
10 definitions and one of those definitions is
11 securities claimants. As I understand it,
12 securities claimants are holders of security claims.
13 Is that correct, Mr. Kalloghlian?

14 MR. WINGFIELD: Well, let's just look at
15 the definition.

16 THE DEPONENT: I have it in front of me.
17 It's at the bottom of paragraph 8 of the
18 RSA, and it says, "'Securities claimants'
19 means the holders of securities claims..."

20
21 BY MR. WRIGHT:

22 27. Q. Right. Securities claimants, as I
23 understand it...I'm just trying to make sure from my
24 client's perspective that I have a clear
25 understanding of the basis on which the motions are

S. Kalloghlian - 10

1 proceeding on Friday, or the motion is proceeding on
2 Friday, that securities claimants include Zola
3 Finance Holdings Limited. Is that correct?

4 A. Securities claimants means the
5 holders of securities claims. To the extent that
6 Zola has a securities claim, it would fall in that
7 definition.

8 28. Q. Okay, and is it your understanding
9 that Zola does have a securities claim?

10 A. Based on the allegations I have
11 reviewed, my understanding is that it has a
12 securities claim.

13 29. Q. Okay. As I understand the position
14 that is being advanced in the action in which you
15 are counsel...and this is really set out at
16 paragraph 20 of your affidavit. The Ontario class
17 action alleges that CannTrust securities traded at
18 artificially inflated prices during the class
19 period. Is that fair?

20 A. That's what it says, yes.

21 30. Q. Sorry, I didn't quite hear you.

22 A. Yes, that is what it says.

23 31. Q. Okay, thanks. The Ontario class
24 action seeks damages equivalent to the inflation in
25 the price of the shares that the class members

S. Kalloghlian - 11

1 acquired during the class period. Is that fair?

2 A. That's part of the recoveries.

3 32. Q. And I take it you're familiar with
4 part 23.1 of the Ontario Securities Act?

5 A. Yes.

6 33. Q. And it contains a formula that
7 applies to assessing damages with respect to
8 misrepresentation claims being advanced under that
9 Act. Isn't that correct?

10 A. Yes.

11 34. Q. And so my understanding is that
12 under that formula, damages arising from
13 misrepresentation claims are a function of the
14 difference between the price paid for the securities
15 and the price after the correction of the
16 misstatement. Is that fair?

17 A. I mean, there are nuances that are
18 being missed, but I don't take issue with the
19 general statement you have made.

20 35. Q. And is the Ontario class, proposed
21 class action, relying on alleged written
22 misrepresentations by the company?

23 A. You're asking if it does rely on
24 alleged written misrepresentations?

25 36. Q. Yes.

S. Kalloghlian - 12

1 A. Yes.

2 37. Q. And does it rely on any other
3 alleged misrepresentations?

4 MR. WINGFIELD: I'm refusing those
5 questions now. This isn't relevant to the
6 representation order, and you're certainly
7 not adverse in interest to the company nor
8 adverse in interest to the proposed
9 representative plaintiffs in this
10 litigation. So these questions are now
11 over the line of inappropriate. /R

12 38. MR. WRIGHT: Sorry, why are they over
13 the line, Mr. Wingfield?

14 MR. WINGFIELD: Because there is no lis
15 between us. There is no possible legal
16 right that is being put in issue in terms
17 of the representation order that would bear
18 upon what is effectively a discovery of our
19 action. So no.

20 39. MR. WRIGHT: Well, I disagree with that.
21 My question is whether the class is relying
22 on any misrepresentations other than the
23 written misrepresentations that it alleges
24 in the Statement of Claim.

25 MR. WINGFIELD: Yes, so you have a

S. Kalloghlian - 13

1 Statement of Claim. You can read it, and
2 I'm not permitting Mr. Kalloghlian to
3 answer questions about the Statement of
4 Claim. It's not a matter on issue for
5 Friday and it's not an appropriate subject
6 of these questions on this cross-
7 examination.

8 40. MR. WRIGHT: Okay, I have your position,
9 Mr. Wingfield.

10
11 BY MR. WRIGHT:

12 41. Q. Mr. Kalloghlian, you have some
13 familiarity with the Zola Statement of Claim you
14 have indicated, correct?

15 A. Yes, I reviewed it.

16 42. Q. And Zola is advancing a
17 misrepresentation claim in its Statement of Claim,
18 correct?

19 MR. WINGFIELD: This is, again, not
20 relevant to the representation order that
21 is being sought, and I'm refusing or
22 instructing Mr. Kalloghlian not to answer
23 that question.

/R

24 Your client has a claim it is
25 pursuing that interest is not subject to

S. Kalloghlian - 14

1 the representation order, they're carved
2 out of it, and therefore, Mr. Kalloghlian's
3 analysis of that claim is irrelevant.
4

5 BY MR. WRIGHT:

6 43. Q. Mr. Kalloghlian, the Zola plaintiff
7 is seeking damages for the full amount of the
8 purchase price paid for their CannTrust shares.
9 You're aware of that?

10 MR. WINGFIELD: It is irrelevant what
11 Zola is claiming. This is a representation
12 order that is being sought. It is not a
13 motion for the prosecution of claims that
14 are in dispute between our respective
15 parties on this motion. /R

16 44. MR. WRIGHT: Okay. I just want to make
17 sure I have your position clearly, Mr.
18 Wingfield, and as I understand it, your
19 position is that it is irrelevant what Zola
20 is claiming. Is that correct?

21 MR. WINGFIELD: No, what I am saying is
22 that on this motion questions about your
23 client's claims are irrelevant.

24 45. MR. WRIGHT: And just so I fully
25 understand your position, and I don't want

S. Kalloghlian - 15

1 to waste anybody's time, you draw a
2 distinction between relevance on this
3 motion and presumably what you are trying
4 to say is this may be relevant at some
5 other point. Am I correct in that?

6 MR. WINGFIELD: Insofar as your
7 representation of your client seeks
8 substantive relief in the context of the
9 CCAA proceedings, you are free to pursue
10 that relief, because the representation
11 order does not purport to represent your
12 client.

13 46. MR. WRIGHT: Okay. Thank you. I
14 understand your position.

15
16 BY MR. WRIGHT:

17 47. Q. I'm going to ask you a few more
18 questions, Mr. Kalloghlian. I appreciate that Mr.
19 Wingfield may object to some of them. We'll see how
20 that goes.

21 The fact that Zola is seeking damages for
22 the full amount of the purchase price paid for their
23 CannTrust shares, that's not a remedy available
24 under part 23.1 of the Securities Act, is it?

25 MR. WINGFIELD: That question is refused.

/R

S. Kalloghlian - 16

1 48. MR. WRIGHT: And refused on what basis?

2 MR. WINGFIELD: It is the same type of
3 question you have asked before. If you
4 wish to advance an argument about your
5 client's legal rights, you may do so. It
6 is not the subject of cross-examination of
7 Mr. Kalloghlian in relation to CannTrust's
8 motion to have a representation order
9 granted in favour of the consortium of law
10 firms.

11 49. MR. WRIGHT: Thank you, Mr. Wingfield.
12 I understand your position.

13
14 BY MR. WRIGHT:

15 50. Q. Mr. Kalloghlian, Zola is also
16 seeking damages for lost returns from alternative
17 investments it would have made with the funds it
18 invested in CannTrust. That's not a claim that's
19 being advanced in your action, is it?

20 MR. WINGFIELD: Again, this is not an
21 appropriate subject of cross-examination
22 for the purposes of the representation
23 order.

/R

24 51. MR. WRIGHT: Thank you. I understand
25 your position, Mr. Wingfield.

S. Kalloghlian - 17

1 BY MR. WRIGHT:

2 52. Q. Mr. Kalloghlian, at paragraph 30 of
3 your affidavit, and just give me a moment while I
4 turn to that, you state at paragraph 30:

5 "...Ontario class action counsel
6 immediately appeared in the CCAA
7 proceedings and took steps to ensure that
8 the rights of securities claimants would
9 not be unfairly compromised..."

10 So as we have reviewed, securities claimants
11 includes Zola. So my question is what steps did
12 Ontario class action counsel take to ensure the
13 rights of Zola would not be unfairly compromised?

14 MR. WINGFIELD: Well, that is the
15 subject of the mediation which, as you
16 know, is also subject to confidentiality
17 provisions. You are aware that there has
18 been extensive negotiations that we have
19 spearheaded on behalf of the securities
20 claimants. That has led at least to the
21 arrangements that are made public in this
22 motion. Other negotiations are ongoing,
23 and beyond that, these questions are
24 inappropriate because they trench upon the
25 privilege that is inherent in the mediation

S. Kalloghlian - 18

1 process.

/R

2 53. MR. WRIGHT: Well, I mean, Mr.
3 Wingfield, you can't have it both ways.
4 You can't make a statement that the rights
5 of security claimants would not be unfairly
6 compromised as a step that the Ontario
7 class action counsel took, and then when I
8 ask what steps were taken, you refuse to
9 answer the question.

10 MR. WINGFIELD: That wasn't actually the
11 question you asked. The question you have
12 been asking is about your client's
13 interests in relation to the mediation is
14 effectively what you have been asking, and
15 those questions are inappropriate for the
16 reasons I have expressed.

17
18 BY MR. WRIGHT:

19 54. Q. Well, let me try and refine the
20 question. I'm looking at paragraph 30. I'm
21 entitled to cross-examine about paragraph 30, and my
22 question is when...Mr. Kalloghlian, when you say
23 Ontario class action counsel took steps to ensure
24 that the rights of security claimants would not be
25 unfairly compromised, that, by definition, includes

S. Kalloghlian - 19

1 Zola.

2 So what steps were taken by Ontario class
3 action counsel to ensure that the rights of Zola
4 would not be unfairly compromised? I haven't said a
5 word about the mediation, Mr. Wingfield.

6 MR. WINGFIELD: You actually have my
7 objection. Again, you act for Zola, and
8 you are advancing claims on behalf of Zola
9 in the mediation, and you are in effect
10 asking about how we have approached the
11 mediation and how that affects Zola's
12 rights or interests in that mediation, and
13 that is entirely inappropriate.

14 55. MR. WRIGHT: No, that's not what I'm
15 asking, Mr. Wingfield.

16 MR. WINGFIELD: Actually it is. You act
17 for Zola. You know you do, and so you're
18 asking about the interaction of your
19 representation of Zola and our
20 representation of the security claimants in
21 the context of the mediation.

22 I'm not permitting those questions
23 to be answered for the reasons I have
24 expressed. You can move to a different
25 topic if you wish.

S. Kalloghlian - 20

1 56. MR. WRIGHT: Mr. Wingfield, this would
2 have been a lot easier if you had just
3 sworn the affidavit instead of Mr.
4 Kalloghlian, but the question I have for
5 you is security claimants includes Zola.
6 There is a statement by Mr. Kalloghlian
7 that steps have been taken to ensure that
8 those rights would not be unfairly
9 compromised, and you're refusing to answer
10 a question about that. Is that correct?

11 MR. WINGFIELD: I'm refusing to
12 answer...have Mr. Kalloghlian answer
13 questions about your client Zola.

14 MR. D'SOUZA: Sorry, if I can assist,
15 I'm not even understanding the question
16 because security claimants is defined the
17 way it's defined. It's not identifying or
18 highlighting or referencing any particular
19 securities claimant. So I'm not sure what
20 your expectation is with respect to the
21 witness protecting one investor's claims.
22 It doesn't make sense.

23 57. MR. WRIGHT: I'm actually just trying to
24 understand what is at paragraph 30. So if
25 my question doesn't make sense, it may be

S. Kalloghlian - 21

1 because I don't understand the statement.
2 I'm trying to ask some questions about
3 that, and I am being met with an objection.

4 MR. D'SOUZA: But isn't the statement
5 self-evident based on the way securities
6 claimants is defined? It includes
7 thousands of people, not one or two or
8 three people that can be singled out.

9 58. MR. WRIGHT: Look, I mean, we can
10 probably agree and disagree on a variety of
11 things, but I don't know how we could agree
12 that a statement that says, "Steps were
13 taken to ensure rights would not be
14 unfairly compromised," is self-evident. I
15 mean, the obvious question is what steps
16 were taken.

17 MR. D'SOUZA: Yes, you can ask what steps
18 were taken, but you have repeatedly been
19 asking what steps were taken with respect
20 to Zola. I mean, Mr. Wingfield may have a
21 further objection, but you know, what I was
22 not understanding is you pinpointing it to
23 Zola.

24 59. MR. WRIGHT: Fine, fair enough. Let's
25 take it step by step.

S. Kalloghlian - 22

1 BY MR. WRIGHT:

2 60. Q. Mr. Kalloghlian, what steps were
3 taken to ensure the rights of security claimants
4 would not be unfairly compromised?

5 A. We appeared at the CCAA proceeding
6 as counsel. We started conversations with the
7 company and with the monitor to ensure that there
8 was a methodology by which the securities claimants'
9 interests could be protected and advanced. We
10 corresponded and made agreements with counsel to the
11 U.S. securities class action members and securities
12 claimants and we attended on...and appeared at
13 motions and made the submission.

14 MR. WINGFIELD: And extensive expert
15 evidence.

16
17 BY MR. WRIGHT:

18 61. Q. Right. One of the securities
19 claimants is Zola, correct?

20 MR. WINGFIELD: Now I'm back to the
21 objection that I made earlier.

/R

22 We're just not going to answer
23 questions about Zola here. You act for
24 Zola. We're not answering questions about
25 Zola.

S. Kalloghlian - 23

1 62. MR. WRIGHT: Okay. So you have got
2 evidence that you took steps to ensure the
3 rights of security claimants which includes
4 Zola would not be unfairly compromised, but
5 you're refusing to answer any questions
6 about steps you took about Zola?

7 MR. WINGFIELD: You are trying to sever
8 Zola from the other security claimants.
9 The steps were taken on behalf of the class
10 of security claimants. That class has been
11 more than effectively represented by the
12 consortium and the coalition, and most of
13 those steps are steps that have been taken
14 in the context of the mediation, which is,
15 as you know, covered by confidentiality
16 orders, and therefore, is not the
17 appropriate subject of examination on this
18 motion.

19 63. MR. WRIGHT: Okay. Well, aside from
20 your self-serving statements, Mr.
21 Wingfield, has the Ontario class action
22 counsel taken any steps to pursue or
23 protect Zola's recision claim?

24 MR. WINGFIELD: I am instructing the
25 witness not to answer questions about Zola,

S. Kalloghlian - 24

1 and we can keep going down this road if you
2 wish, but you'll be met with the same
3 refusals, that Zola is not subject to the
4 representation order. You represent Zola
5 and this is a motion brought by CannTrust
6 to seek an order that allows the consortium
7 and coalition to represent the interests of
8 securities holders generally, excluding
9 from that order your client. /R

10
11 BY MR. WRIGHT:

12 64. Q. Does the restructuring support
13 agreement assign any value to Zola's rescission claim?

14 MR. WINGFIELD: That is, again, not the
15 subject of this motion. The restructuring
16 agreement is not, as far as I'm aware, in
17 issue on Friday. /R

18 65. MR. WRIGHT: Well, it's included in the
19 motion record. So counsel for the company
20 must have thought it was relevant, or it
21 wouldn't have been included in the motion
22 record, and I think I'm entitled to ask
23 questions about a document that has been
24 placed into the motion record.

25 MR. D'SOUZA: No, only in as far as it's

S. Kalloghlian - 25

1 relevant to an issue on the motion.

2 Otherwise, you would be asking questions
3 about the pleadings that have been
4 attached.

5 66. MR. WRIGHT: Well, it seems to be that
6 I'm not allowed to ask any questions about
7 the restructuring support agreement. Is
8 that your position?

9 MR. D'SOUZA: You're allowed to ask
10 questions that go to the motion, which is
11 whether or not the proposed representatives
12 are appropriate. If you limit your
13 questions to those...

14 67. MR. WRIGHT: One of the questions I have
15 in that regard is whether the proposed
16 representatives are appropriate. I am
17 asking Mr. Kalloghlian did the proposed
18 representatives assign any value to Zola's
19 recision claim.

20 MR. WINGFIELD: And you have the
21 objection on the record already to
22 questions about Zola, because Zola is not
23 the subject of this representation order.
24 Zola is not affected by this order. You
25 represent Zola, and your substantive

S. Kalloghlian - 26

rights, or Zola's substantive rights are yet to be dealt with because the CCAA process has not yet run its course.

68. MR. WRIGHT: Thank you, Mr. Wingfield.
I have your position.

BY MR. WRIGHT:

69. Q. Mr. Johnson put an affidavit...or a sworn affidavit that is included in this motion. He does not say anything in his affidavit...I'm happy for you to look at it, Mr. Kalloghlian, if you need to, about multi-party mediation being unworkable, but at paragraph 32 of your affidavit you state that:

"...It soon became clear that a multi-party mediation would be unworkable..."

Why do you say that?

A. It did not...and I'm being careful so as not to divulge confidential info, but it...sorry, the question was why did it appear that way?

70. Q. Why does it appear to you? When you say:

"...It soon became clear that such a multi-party mediation would be unworkable..."

S. Kalloghlian - 28

1 MR. WINGFIELD: Well, Mr. Kalloghlian
2 answered your question. I just restated
3 what he told you.

4 74. MR. WRIGHT: Well, I don't need you to
5 restate your witness' answer. If you have
6 an objection, obviously put it on the
7 record, but otherwise, I have a cross-
8 examination I'm trying to conduct.

9
10 BY MR. WRIGHT:

11 75. Q. So Mr. Kalloghlian, when was it
12 determined that a multi-party mediation would be
13 unworkable?

14 A. Early on.

15 76. Q. And who made that determination?

16 A. It doesn't say that anyone
17 determined that. It became clear. It says:

18 "...It became clear that such a mediation
19 would be unworkable..."

20 77. Q. Became clear to whom?

21 A. It was clear to me.

22 78. Q. And was it clear to anybody else?

23 A. What is that question?

24 79. Q. Well, you said it was clear to you.

25 Are you aware of whether it became clear to anybody

S. Kalloghlian - 29

1 else?

2 A. Yes. It appeared to me...I don't
3 live in other people's heads, but it seemed pretty
4 clear to me that other people also believed it was
5 unworkable.

6 80. Q. Okay, I'm not asking you to live in
7 anybody's heads, but in terms of information that
8 was provided to you, did anybody else communicate to
9 you that they thought a multi-party mediation was
10 unworkable?

11 MR. WINGFIELD: The answer to that
12 question is yes, because I'm aware of the
13 answer to that question, and the answer to
14 that question is also subject to the
15 privilege that the mediation is being
16 conducted under.

17
18 BY MR. WRIGHT:

19 81. Q. Mr. Kalloghlian, at any time did you
20 discuss with counsel for Zola that you had reached
21 the conclusion that a multi-party mediation was
22 unworkable?

23 MR. WINGFIELD: That again is subject to
24 the mediation privilege. As you know, Mr.
25 Wright, we have had extensive discussions

S. Kalloghlian - 30

1 in the context of the mediation about your
2 clients' claims, and you are fully aware
3 that those conversations are subject to
4 the mediation privilege. /R

5
6 BY MR. WRIGHT:

7 82. Q. Okay. At paragraph 33 of your
8 affidavit you estimate that the classes you propose
9 to represent constitute 98 percent of total damages
10 suffered by securities claimants represented in
11 these proceedings. What is that based on?

12 A. That's based on analysis we did in
13 consultation with our damages experts.

14 83. Q. And so what is in the two percent
15 that is not represented in these proceedings?

16 A. I don't understand the question.

17 84. Q. The statement you made in your
18 affidavit is that the coalition estimates that it
19 represents a proposed class with an estimated 98
20 percent of the total damages within that class or
21 within the proceedings. So what is in the two
22 percent that is not part of the 98 percent?

23 A. Those are damages that are...so
24 there is a universe of claimants represented in this
25 proceeding. We have proposed to represent everyone

S. Kalloghlian - 31

1 except those represented by you and other counsel
2 that have appeared.

3 This statement is that...says that
4 excluding Zola and the other entities that have
5 appeared...98 percent of the damage suffered by
6 everyone would have been suffered by securities
7 claimants excluding Zola and the other individuals
8 represented individually in this proceeding.

9 85. Q. And you said that you got that
10 information from your damages expert?

11 A. We arrived at that estimate in
12 consultation with our damages expert and using
13 information, yes, with our damages expert and
14 information available to us.

15 86. Q. And how did you assess Zola's
16 damages in order to arrive at that?

17 A. We created a trading model and we
18 ran your trades through, Zola's trades, through
19 them.

20 87. Q. Okay, and so the trading model would
21 have provided an estimate of Zola's damages. Is
22 that correct?

23 MR. WINGFIELD: I'm not permitting the
24 witness to answer those questions for the
25 reasons I have expressed already on the

S. Kalloghlian - 32

record.

/R

BY MR. WRIGHT:

88. Q. Okay. I take it, Mr. Kalloghlian, when you ran Zola's damages through a trading model, it means that you didn't actually take into account Zola's actual damages, correct?

MR. WINGFIELD: We are not answering questions about Zola.

/R

You act for Zola and you have, as I said before, the ability to represent Zola independently of the proposed representation order, and I presume that you will do so.

89. MR. WRIGHT: Okay, just to be clear, I'm asking these questions because Mr. Kalloghlian has a statement in his affidavit addressing the fact that the coalition estimates that it represents 98 percent of the total damages.

I'm trying to understand first what the two percent is composed of, and secondly, how that two percent was arrived at, and you're refusing to let me ask questions about the second point I'm trying

S. Kalloghlian - 33

1 to address.

2 MR. WINGFIELD: No, you actually asked
3 questions about both of those points and
4 obtained answers in respect of those
5 points.

6 90. MR. WRIGHT: Right, and I have more
7 questions which you're refusing.

8 MR. WINGFIELD: In relation to Zola,
9 yes.

10 MR. D'SOUZA: Mr. Wright, whether it's
11 two percent or 70 percent or 60 percent,
12 what turns on it for the purposes of the
13 representation order?

14 91. MR. WRIGHT: Well, it's...what turns on
15 it is that it's at paragraph 33 of Mr.
16 Kalloghlian's affidavit, and he has come
17 up, in conjunction with a damages expert,
18 with an estimate of the percentage of total
19 damages that the coalition represents. I
20 would have thought I'm entitled to cross-
21 examine on that, and I have been allowed to
22 ask some questions and then I have had
23 objections to further questions.

24 MR. D'SOUZA: But again, what could
25 possibly turn on this with respect to the

S. Kalloghlian - 34

1 representation order? You have still not
2 explained that.

3 92. MR. WRIGHT: I think we're getting this
4 kind of backwards, Mr. D'Souza. I'm asking
5 about evidence you have put in in support
6 of your motion. I don't actually have
7 to...I don't have to actually prove why I'm
8 asking about it, because you have put it
9 into evidence and now I get to cross-
10 examine about it.

11 MR. D'SOUZA: Well, you get to cross-
12 examine on something that's relevant, not
13 on things that are irrelevant, but just
14 happen to be in the record.

15 93. MR. WRIGHT: So you're telling me that
16 paragraph 33 of Mr. Kalloghlian's affidavit
17 is irrelevant?

18 MR. WINGFIELD: We have had a discussion
19 about this paragraph in relation to the
20 basis of the information that Mr.
21 Kalloghlian testifies to, and you have
22 obtained answers as to how that number came
23 to be, and the analysis that was performed
24 to generate that number, and therefore, you
25 have answers to the questions that you have

S. Kalloghlian - 35

1 asked. Beyond that, it becomes irrelevant.

2 94. MR. WRIGHT: I have your position.

3 Thank you.

4
5 BY MR. WRIGHT:

6 95. Q. Mr. Kalloghlian, at paragraph 39 of
7 your affidavit you describe the representation order
8 and what...part of what the benefit is that you see
9 from that, and my question is what claims is the
10 coalition seeking to resolve as representative
11 counsel?

12 MR. WINGFIELD: Well, the answer to that
13 question is heavily...

14 96. MR. WRIGHT: Sorry, how is this not an
15 answer that Mr. Kalloghlian, as the
16 witness, can provide, Mr. Wingfield?

17 MR. WINGFIELD: Because Mr. Wright, you
18 persist in...

19 97. MR. WRIGHT: Do you have any objection?

20 MR. WINGFIELD: I do, because you
21 persist in asking questions that are
22 inherent to the mediation process.

23 98. MR. WRIGHT: Then just make your
24 objection, Mr. Wingfield. I don't need an
25 answer. I just need an objection from you.

S. Kalloghlian - 36

1 MR. WINGFIELD: Well, then, you have my
2 objection. /R

3 I was hoping to find some way to
4 answer part of the question, but I will
5 give you an objection to the totality of
6 the question because it does require
7 consideration of the mediation process.

8 99. MR. WRIGHT: Okay, how would this
9 consider the mediation process?

10 MR. WINGFIELD: You have asked what
11 claims are being compromised. Those claims
12 are being compromised in the context of the
13 mediation.

14 100. MR. WRIGHT: Okay. So because that's
15 part of the mediation process...I don't
16 actually think that's what I was asking.
17 What I was asking was what are the claims
18 the coalition is seeking to resolve. My
19 understanding is it's the security claims.

20 MR. WINGFIELD: The coalition is seeking
21 to resolve claims that are relevant to the
22 securities claimants in relation to all the
23 causes of action that arise to be
24 considered in the context of the mediation.

25 101. MR. WRIGHT: Okay. Did the coalition

S. Kalloghlian - 37

1 negotiate the restructuring support
2 agreement with the company?

3 MR. WINGFIELD: Mr. Kalloghlian, you can
4 answer that question.

5 THE DEPONENT: Yes.

6
7 BY MR. WRIGHT:

8 102. Q. And did the coalition at any time
9 include Zola or advise Zola about those
10 negotiations?

11 MR. WINGFIELD: Well, you would know the
12 answer to that question, Mr. Wright,
13 because you represent Zola, and so we don't
14 need to answer that question.

15 103. MR. WRIGHT: No, you do need to answer
16 it, because I'm entitled to put this on the
17 record. I'm not a witness here. I'm a
18 lawyer. I'm asking Mr. Kalloghlian an
19 entirely proper question.

20 THE DEPONENT: You asked two questions.
21 You said "involve or advise".

22
23 BY MR. WRIGHT:

24 104. Q. Yes.

25 A. We advised you what was going on.

S. Kalloghlian - 38

1 105. Q. You advised Zola...you're saying
2 under oath you advised Zola you were negotiating a
3 restructuring support agreement?

4 A. No, sorry, no, I didn't understand
5 the question. I thought it was with respect to the
6 mediation process. No, we did not advise them.

7 106. Q. Okay. At paragraph 11 of your
8 affidavit...sorry, it's just taking me a moment to
9 go to it. At paragraph 11 of your affidavit you
10 indicate that:

11 "...Following implementation of the CCAA
12 plan, CannTrust will consent to orders
13 permitting the plaintiffs in the class
14 actions to obtain an expedited trial
15 date..."

16 And that's to prosecute which claims?

17 A. It says here:

18 "...on an expedited basis a joint trial
19 date for the prosecution of the class
20 actions and any assigned claims..."

21 107. Q. Okay. That does not include the
22 Zola claims, does it?

23 A. The Zola claims? I'm not sure what
24 you mean by "Zola claims". We're going to be
25 asserting claims, class action claims and assigned

S. Kalloghlian - 39

1 claims. I mean, when you say "claim" if you're
2 talking about the Statement of Claim which Zola has
3 commenced and allegations in there, no, we will not
4 be asserting that claim.

5 108. Q. In particular I think what I'm
6 really referring to is the misrepresentation claim
7 and the recision claim that Zola is advancing.
8 Those aren't part of the claims you would be seeking
9 to try on an expedited basis, are they?

10 MR. WINGFIELD: Well, just one second.
11 The claims that are going to be tried are
12 claims that are not going to be settled as
13 part of the mediation. So it's difficult
14 to answer your question in the abstract,
15 because we do not know today what claims
16 will remain as unsettled claims at the end
17 of CannTrust's CCAA proceedings.

18 Sitting here today, we have resolved
19 only claims against CannTrust, and you have
20 seen that in the restructuring agreement.

21 MR. D'SOUZA: Mr. Wright, I'm not sure I
22 understand even some of the points in the
23 question, because I believe that Hurusa and
24 Singh claims do assert common law
25 misrepresentation claims, and do seek

S. Kalloghlian - 40

1 recision on behalf of certain putative
2 plaintiffs, and I believe your client is
3 seeking recision against Mr. Litwin, who is
4 not part of the settling group here.

5 109. MR. WRIGHT: No, against CannTrust.

6 MR. D'SOUZA: Well, your client didn't
7 buy shares directly from CannTrust. So
8 that claim on its face...

9 110. MR. WRIGHT: Oh, I understand.

10 MR. D'SOUZA: ...I'm not sure it's
11 tenable.

12 111. MR. WRIGHT: I have to go back and
13 check. I believe it's against both.

14 MR. D'SOUZA: Yes, I mean, you can seek
15 it against anyone you want, but you didn't
16 buy shares from CannTrust. I'm not sure
17 about the viability of that claim.

18 112. MR. WRIGHT: Well, we can debate the
19 viability of all kinds of claims. The
20 question...when there is a debate about
21 viability, that's why you have a trial, Mr.
22 D'Souza. So my question is if the Zola
23 claims are not resolved, are they to be
24 included in the claims that are to be
25 expedited?

S. Kalloghlian - 41

1 MR. WINGFIELD: Paragraph 11 on its face
2 says that:

3 "...CannTrust will in the future
4 consent to orders permitting claims
5 to be prosecuted on an expedited
6 basis..."

7 Those claims are claims that will be extant
8 at the time that CannTrust is emerging from
9 the CCAA process, right, following
10 implementation of the CCAA plan. So we
11 don't know what those are sitting here
12 today. There may be none. There may be
13 many. We do not know today.

14 113. MR. WRIGHT: Mr. Kalloghlian, given the
15 objections which we will address in the
16 most appropriate way, those are my
17 questions. Thank you for your time this
18 afternoon.

19 MR. D'SOUZA: Thank you.

20 THE DEPONENT: Thank you.

21
22 --- upon adjourning at 4:44 p.m.

S. Kalloghlian - 42

INDEX OF REFUSALS

<u>REFUSAL NO.</u>	<u>PAGE NO.</u>	<u>QUESTION NO.</u>
1.	12	37
2.	13	42
3.	14	43
4.	15	47
5.	16	50
6.	18	52
7.	22	61
8.	24	63
9.	24	64
10.	27	71
11.	30	81
12.	32	87
13.	32	88
14.	36	98

REPORTER'S NOTE:

Please be advised that any undertakings, objections, under advisements and refusals are provided as a service to all counsel, for their guidance only, and do not purport to be legally binding or necessarily accurate and are not binding upon Victory Verbatim Reporting Services Inc.

I hereby certify the foregoing to be a true and accurate transcription of the above noted proceedings held before me on the **27th DAY OF JANUARY, 2021** and taken to the best of my skill, ability and understanding.



Certified Correct:

Conner McTague
Verbatim Reporter

IN THE MATTER OF THE COMPANIES' CREDITORS' ARRANGEMENT
ACT, R.S.C. 1985, c. C-36, AS AMENDED AND IN THE MATTER OF A
PLAN OF COMPROMISE OR ARRANGEMENT OF CANNTTRUST
HOLDINGS INC. ET AL.

Court File No.: CV-20-00638930-00CL

ONTARIO

**SUPERIOR COURT OF JUSTICE
(COMMERCIAL LIST)**

Proceeding commenced at Toronto

MOTION RECORD

(Responding to Proposed CC44 Representation Order)

Siskinds LLP

680 Waterloo Street

P.O. Box 2520

London, ON N6A 3V8

Michael G. Robb (LSO#: 45787G)

Garett M. Hunter (LSO #: 71800D)

Tel: 519-660-2121

Fax: 519-672-6065

Barristers & Solicitors

100 Lombard Street

Suite 302

Toronto, ON M5C 1M3

Alex Dimson (LSO#: 56129U)

Tel: 416-594-4394

Fax: 416-362-2610

Lawyers for the Plaintiff

Wright Henry LLP

200 Wellington St. West

Suite 602

Toronto, ON M5V 3C7

Michael Wright

Danielle Stampley

Tel: 416-306-8280

Fax: 416-306-8281